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ABSTRACT 
 
In cells undergoing stress, the p53 transcription factor is stabilized and 
activates the expression of numerous genes contributing to p53-mediated tumor 
suppression. One p53 target gene is Mdm2, which encodes an oncoprotein that 
binds and ubiquitinates p53 for proteasomal degradation, thus limiting the 
amplitude and duration of the p53-mediated stress response. Our lab recently 
discovered that Mdm2 phosphorylation by ATM and c-Abl regulates the DNA 
damage response and tumorigenesis in mice. AKT has also been found in 
transfection studies to phosphorylate Mdm2 at serine residues 166 and 186 
(mouse S163 and S183) to alter p53 activity. However, the physiological 
significance of Mdm2 phosphorylation by Akt remains unknown. Therefore, I 
generated Mdm2S163A or Mdm2S183A mice expressing mutant Mdm2 incapable of 
being phosphorylated by Akt.  
In contrast with our previous studies, Akt phosphorylation of Mdm2 does 
not alter spontaneous tumorigenesis or the DNA damage response to ionizing 
radiation. However, Akt phosphorylation of Mdm2-S183 (but not -S163) 
upregulates nuclear localization of Mdm2, destabilizes p53, and reduces p53-
mediated senescence in response to elevated levels of reactive oxygen species 
(ROS). To examine the effects of Mdm2-S183 phosphorylation on p53 tumor 
suppression, I utilized three different mouse models of ROS-induced cancer. 
Increased levels of p53 and senescence in Mdm2S183A mice yielded reduced 
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tumorigenesis in an activated Ras model of lung cancer, a phorbal ester-induced 
skin cancer model, and a diethylnitrosamine-induced model of hepatocellular 
carcinoma. Since AKT is also important regulator of cell metabolism, I explored 
the impact of the Mdm2-S183 allele on metabolic functions. Mdm2 
phosphorylation by Akt reduced glucose metabolism via glycolysis in vitro, and 
reduced insulin tolerance in mice, without altering glucose tolerance and glucose-
stimulated insulin secretion. Collectively, these findings document a unique 
physiologic role for the AKT-Mdm2-p53 signaling axis in regulating cell growth 
and tumorigenesis.   
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 CHAPTER I: INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
  
2 
p53 protein: A historical perspective. 
 
p53 was first discovered in the late 1970s as an antigen that coprecipitated 
with antisera against the simian virus SV40 large T antigen (Lane and Crawford, 
1979, Linzer and Levine, 1979). Earlier studies suggested the protein to be an 
oncogene since p53 expression led to cellular transformation (Jenkins et al., 
1985, Eliyahu et al., 1984). Additionally, p53 was also highly expressed in some 
tumors (Jenkins et al., 1985, Sarnow et al., 1982). Soon evidence began to 
emerge showing that various forms of p53 were expressed in tumors (Mowat et 
al., 1985) and that some of them, which were later shown to be mutant, 
possessed the ability to transform cells. However, the role of p53 in tumor 
suppression was demonstrated by the fact that wild type p53 cDNA suppressed 
the transformation of cells in vitro (Eliyahu et al., 1989).  
 
The role of wild type p53 as a tumor suppressor protein was further 
demonstrated by studies showing that cellular stresses like DNA damage 
activated p53 (Maltzman and Czyzyk, 1984, Kastan et al., 1992, Hall et al., 
1993). Activated p53 was able to block cell cycle progression and promoted 
apoptotic cell death in response to DNA damage (Lowe et al., 1993, Yonish-
Rouach et al., 1991). The role of p53 as a tumor suppressor was further 
demonstrated by the generation of a mouse model that lacked p53 and turned 
out to be susceptible to tumorigenesis (Donehower et al., 1992). Further 
characterization of wild type p53 showed that it was a DNA binding transcription 
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factor (Kern et al., 1991, Funk et al., 1992, Zambetti et al., 1992), that activated 
the expression of genes like p21 to halt cell cycling (el-Deiry et al., 1993). 
Additionally, it was also demonstrated that wild type p53 activated the expression 
of Mdm2 (Barak et al., 1993) which is its well-established negative regulator. 
 
p53 protein domains  
 
The p53 protein contains several domains that play pivotal roles in its 
function as a transcription factor (Figure 1). The N-terminus contains two 
transactivating domains (TADs), namely TAD1(amino acids 1-40) and TAD2 
(amino acids 41-61). These are followed by a proline rich domain (PRD) domain 
(amino acids 64-92). The domain that binds to DNA (DBD) (amino acids ~100–
300) spans the central region of the p53 protein peptide sequence. This is 
followed by an oligomerization domain (OD) (amino acids 323-355), and lastly C-
terminal domain (CTD) (amino acids 364-393) which is largely unstructured. 
 
 
 
 
 
  
 
 
 
 
 
Figure 1.1. Schematic representation of the several p53 polypeptide 
domains. The N terminus contains the two transactivation domains shown in 
blue, followed by the proline rich domain in yellow, then the central DNA 
binding domain in light green and the c-terminal is comprised of the 
oligomerization domain in orange and the C-terminal domain depicted here in 
dark green. 
TAD2 TAD2 PRD DBD OD CTD
0                                  100                                                 200                            300    393       
 
  
4 
The function of p53 as a transcription factor requires its binding to DNA to 
regulate the transcription of genes. p53 monomers oligomerize and function as 
tetramers with direct DNA binding capacity (Friedman et al., 1993). The central 
DBD is crucial for p53 function since this region  interacts with p53 response 
elements on DNA (el-Deiry et al., 1992). DNA binding enables the interaction of 
p53 TADs with various effector proteins to facilitate target gene expression (Qian 
et al., 2002). Additionally, the DBD is the most mutated region of p53 in most 
human cancers with several hotspot mutations that result in loss of DNA binding 
ability (Hollstein et al., 1991). 
 
The two TADs are important for p53 function as a transcription factor since 
they add a layer of specificity, with each TAD activating a different set of p53 
target genes (Brady et al., 2011). Mice expressing mutant p53 harboring 
inactivating mutations in both TAD1 and TAD2 do not express the vast majority 
of direct p53 target genes and are susceptible to tumorigenesis (Brady et al., 
2011). Mice expressing inactivating mutations in either of the TADs, are able to 
suppress tumorigenesis, suggesting that these domains activate distinct gene 
sets and pathways that can mediate tumor suppression in the absence of the 
other.  
 
The CTD plays an important role in regulating gene expression by mediating 
the scanning of DNA for p53 response elements (Tafvizi et al., 2011, Tafvizi et 
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al., 2008, Khazanov and Levy, 2011) and stable DNA binding (Laptenko et al., 
2015). Structural determination studies have shown that the CTD is very 
disorganized and this facilitates the binding of a myriad of other regulatory 
proteins and RNAs that regulate p53-mediated transcription (Laptenko et al., 
2016). In addition, this domain is subject to various post-translational 
modifications further adding to the complexity of the CTD's role in transcription 
(Mujtaba et al., 2004, Tong et al., 2015b, Tong et al., 2015a). As such, various 
mouse models and cell lines expressing p53 protein lacking segments of the 
CTD display different phenotypes in terms of p53 gene expression and tumor 
suppression, further highlighting complex role of this region of p53-depent 
transcriptional regulation (Feng et al., 2005, Krummel et al., 2005, Simeonova et 
al., 2013, Hamard et al., 2013). 
 
p53 mouse models 
 
The gene encoding the p53 transcription factor protein is often mutated in 
human cancer. Observations from human tumors and p53 null and mutant mice, 
underscores the role of p53  as a potent tumor suppressor. Mice deficient for p53 
(p53-/-) or heterozygous for p53 loss (p53+/-) are susceptible to highly penetrant 
spontaneous tumors (Donehower et al., 1992). The tumor incidence for p53-/- 
mice is about 4 months and all mice will succumb to cancer by 10 months of age 
(Donehower, 1996). As for p53+/- mice, the median tumor incidence is about 18 
months (Venkatachalam et al, 1998, Harvey et al., 1995). p53-/- mice present 
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mainly with T cell lymphomas, whereas p53+/- mice display a range of tumors 
predominantly sarcomas and carcinomas, together with some B cell lymphomas 
(Jacks et al., 1994, Purdie et al., 1994). About half of p53+/- mice lose the wild 
type p53 allele (Venkatachalam et al., 1998), suggesting that p53-/- cells are 
selected for and constitute the majority of the tumor cells. Additionally, this 
suggests that p53 alleles act in a recessive manner and loss of both p53 alleles 
facilitates the development and progression of tumors. Consistently with the role 
of p53 as a tumor suppressor, individuals who inherit a mutant allele of p53, such 
as in Li Fraumeni syndrome, are predisposed to develop various types of cancer 
primarily sarcomas and breast cancers (Li et al., 1988). Therefore, the fact that 
about 50% of all human cancers harbor p53 mutations and that mice lacking fully 
functional alleles of p53 are susceptible to cancer, underscores the role of the 
p53 transcription factor protein in tumor suppression. 
  
In human cancers, most mutations in p53 are not inherited like in the case Li 
Fraumeni, but are missense mutations that occur in hot spot regions such as the 
DBD. Most often, p53 mutants act in a gain of function manner, conferring growth 
advantage to cells in vitro and in vivo (Brosh and Rotter, 2009).  Such hotspot 
mutations that alter p53’s ability to bind DNA include the widely studied p53R172H 
and p53R270H, both of which promote cell growth and transformation both in vitro 
and in vivo (Brosh and Rotter, 2009). Genetically engineered mice homozygous 
for both the R172H and R270H alleles are highly susceptible to metastatic 
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tumors (Liu et al., 2000, Lang et al., 2004, Olive et al., 2004). This suggests that 
some full length p53 mutant proteins acquire new functions unlike those of wild 
type p53 to promote tumorigenesis in vivo. Moreover, this highlights the 
importance of wild type p53 DBD in mediating tumor suppression. 
 
Role of p53-dependent transcription in tumor suppression 
 
p53 mainly exerts its function as a potent tumor suppressor through 
transcriptional activation of genes that control processes like cell cycle arrest, 
senescence, DNA damage repair, and apoptosis. Most of the p53 mutations 
present in human cancers are located within the DBD (Olivier et al., 2010) and 
often result in altered p53-mediated transcriptional activity. Central to p53-
dependent transcriptional regulation of tumor suppression are consensus DNA 
sequences called response elements (REs). Canonical p53 REs consist of two 
RRRCWWGYYY decamer motifs, in which R is a purine, W is A or T, and Y is a 
pyrimidine with 0–13bp spacer sequences in between (el-Deiry et al., 1992).  p53 
binds to REs in the form of a tetramer and interact with components of the 
transcriptional machinery, either to activate or repress the expression of its target 
genes. 
 
One of the first p53-target genes to be identified is the cyclin-dependent kinase 
(CDK) inhibitor p21, which triggers cell cycle arrest (Harper et al., 1993). p21 
inhibits CDK-mediated hyperphosphorylation of retinoblastoma protein (Rb) and 
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hypophosphorylated Rb binds and inhibits E2F regulatory proteins thereby 
impeding cell cycle progression (Harper et al., 1993, el-Deiry et al., 1993). It is 
well established that p21 also mediates cellular senescence and is 
overexpressed in senescent human and mouse fibroblasts (Abbas and Dutta, 
2009, Noda et al., 1994). p53 also activates p21 in the presence of ROS resulting 
in senescence (Macip et al., 2002).   
 
p53 also triggers the expression of genes that induce apoptosis. Early 
studies showed that ectopic p53 expression can induce apoptosis in p53-
deficient leukemic cells (Yonish-Rouach et al., 1991). Furthermore, loss of p53-
mediated apoptosis in p53-/- mice was shown to promote tumorigenesis 
(Symonds et al., 1994). To trigger apoptosis, p53 binds to REs of various genes 
such as those of the pro-apoptotic Bcl2-family of proteins. In particular, p53 
triggers the expression of proapoptotic gene Bax, and it was demonstrated that 
Bax mRNA and protein expression are greatly diminished in p53-/- mice 
(Miyashita et al., 1994). MEFs that are Bax deficient are refractory to p53-
dependent apoptosis triggered by oncogene expression (McCurrach et al., 1997). 
Moreover, p53 induces the expression of pro-apoptotic BH-3 family of proteins 
including Puma  (Nakano and Vousden, 2001) and Noxa (Oda et al., 2000). The 
expression of these genes among others often result in mitochondria dependent 
activation of caspases and apoptosis.  
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Cell cycle arrest, senescence, and apoptosis constitute the most studied, 
or rather, canonical mechanisms through which p53 target genes mediate tumor 
suppression. Several mouse models expressing p53 with mutations in the 
transactivation domains have been generated. For instance, inactivating 
mutations in TAD1 in mice (p5325,26) blocks the expression of p53-target genes 
that mediate cell cycle arrest and apoptosis in response to DNA damage but 
retained the ability to suppress oncogene-induced tumorigenesis (Brady et al., 
2011). Surprisingly, mice with inactivating mutations in TAD2 (p5353,54) retained 
the ability to transactivate most genes and displayed unaltered tumor 
suppression (Brady et al., 2011). However, complete inactivation of both TADs in 
p5325,26,53,54 mice, inhibits p53-dependent senescence and the expression of 
most p53-target genes. The expression profile of p5325,26,53,54 mice is 
indistinguishable from that observed in p53-/- mice. Furthermore, p5325,26,53,54 
mice are susceptible to tumorigenesis (Brady et al., 2011, Johnson et al., 2005), 
suggesting that p53 transactivates specific subsets of genes crucial for tumor 
suppression. 
 
Another mouse model in which three lysine residues in the DBD of p53 
are mutated to arginine residues (p533KR) also fail to undergo cell cycle arrest, 
senescence, and apoptosis, but are able to suppress spontaneous tumorigenesis 
(Li et al., 2012a). Interestingly, p533KR mice are still able to properly regulate 
cellular metabolism and oxidative stress responses. Lastly, cells derived from 
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p21−/−;puma−/−;noxa−/− mice fail to undergo cell cycle arrest, senescence, and 
apoptosis (Valente et al., 2013). However, unlike p53-/- mice, 
p21−/−;puma−/−;noxa−/−  mice do not develop tumors and mount an effective DNA 
damage response (Valente et al., 2013).  
 
In the aforementioned studies,  p53-mediated cell cycle arrest, senescence, 
and apoptosis in response to DNA damage were partially or completely ablated, 
but tumor suppression was still maintained. This suggests that p53-mediated 
processes that modulate responses to acute DNA damage are not fully critical for 
p53-dependent tumor suppression. Additionally, these findings suggest a role for 
other compensatory pathways as major contributors to p53-dependent 
suppression of tumorigenesis. Furthermore, this also supports a role for less fully 
understood non-canonical p53 functions such as the regulation of oxidative 
stress responses and cellular metabolism briefly described below.  
 
Relationship between p53 and oxidative stress 
 
Tight regulation of cellular oxidative stress from deregulated ROS is critical 
for tissue homeostasis. Oxidative stress can trigger senescence, cell cycle arrest, 
apoptosis (Liang et al., 2013), and ferroptosis (Jiang et al., 2015). Studies have 
shown that increased levels of ROS play a critical role in tumorigenesis. For 
instance, p53-/- mice exhibit elevated intracellular levels of ROS which can be 
counteracted by administration of the dietary antioxidant N-acetyl cysteine, 
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resulting in reduced lymphoma incidence and reduced growth of liver cancer 
xenografts (Sablina et al., 2005). Additionally, despite the lack of canonical p53-
depedent processes thought to mediate tumor suppression in the previously 
mentioned p533KR model, these mice were not susceptible to developing 
lymphomas as seen in p53-/- mice (Li et al., 2012a). However, these mice were 
able to properly regulate the production of ROS, suggesting that p53-mediated 
regulation of oxidative stress responses may contribute to tumor suppression. 
 
Emerging evidence shows that p53 is involved in regulating various genes 
required for properly modulating the effects and levels of ROS. The main source 
of ROS in cells is oxidative phosphorylation in the mitochondria. p53 promotes 
oxidative phosphorylation but also counteracts ROS effects through the 
transcriptional activation of genes that mediate antioxidant activity (Liu et al., 
2008). Physiological levels of oxidative stress trigger p53-dependent genes with 
antioxidant functions such as ALDH4, Sestrin 1&2, GLS2, GPX1, and Tigar (Hu 
et al., 2010, Liu et al., 2008, Budanov et al., 2004, Bensaad et al., 2006, Tan et 
al., 1999). Tigar alters glycolysis by inhibiting phosphofructokinase 1 which is a 
critical enzyme in glycolysis, thereby leading to enhanced production of NADPH 
which has antioxidant properties (Bensaad et al., 2006). Both GPX1 and GLS2 
are powerful antioxidant enzymes that help scavenge peroxides in cells (Tan et 
al., 1999, Hu et al., 2010). Additionally, Sestrins 1&2 promotes the generation of 
peroxiredoxins, which like NADPH, exhibit immense antioxidant activity (Budanov 
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et al., 2004). Expression of p53-inducible Aldh4 in vitro lowers the levels of ROS 
induced by treatment with hydrogen peroxide or UV (Yoon et al., 2004). 
 
Alternatively, in the presence of excessive oxidative stress p53 triggers the 
expression of pro-oxidant genes including Puma, Pig3, p21, and Bax (Liu et al., 
2008). Pro-oxidant genes such as Pig3 and Puma cause apoptosis (Nakano and 
Vousden, 2001, Johnson et al., 1996). p21 expression in the presence of 
elevated levels of ROS causes senescence (Passos et al., 2010, (Macip et al., 
2002). Furthermore, during chronic exposure to oxidative stress, p53 can induce 
more ROS (Liu et al., 2008), and this can promote the death of cells potentially 
harboring harmful mutations from DNA oxidation. 
 
The seemingly cyclic relationship between p53 and oxidative stress is 
complex and is not yet fully understood. However, both pro-oxidant and 
antioxidant functions of p53 can promote clearance of potentially oncogenic cells. 
Tumor progression is often characterized by increased ROS levels, but cancer 
cells survive probably due to loss of p53 function or through other context-
dependent mechanisms. Therefore, it is plausible that in different contexts, when 
cell cycle arrest, senescence, and apoptosis are impaired, p53-mediated 
regulation of redox homeostasis contributes to tumor suppression. It is also 
possible that all or a combination of these processes work together in unison to 
suppress tumorigenesis. 
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Role of p53 in glucose metabolism 
 
Cancer cells are known to undergo metabolic reprogramming to fulfill the 
higher energy demands required for rapid proliferation characteristic of 
cancerous cells. In particular, it is well established that cancer cells metabolize 
glucose mainly through aerobic glycolysis and not oxidative phosphorylation, a 
process known as the Warburg effect (Warburg, 1956). Since aerobic glycolysis 
is less efficient at ATP generation compared to oxidative phosphorylation, cancer 
cells typically exhibit much more elevated glucose uptake compared to 
untransformed cells . Additionally, utilizing aerobic glycolysis may be potentially 
beneficial to highly vascularized tumors since inefficient generation of ATP would 
not pose energy deficits due to a plentiful supply of nutrients from blood. 
Moreover, it is possible that glucose is not mainly required to generate ATP 
during nutrient abundance, but used for the biosynthesis of macromolecules like 
lipids, and carbohydrates. As a result, cancer cells can still survive and rapidly 
proliferate despite using glycolysis as a major process to generate energy. 
 
Accordingly, several oncogenes have been shown to promote glycolysis.  
For instance, Akt enhances glucose uptake in cancer cell by promoting cell 
surface localization of glucose transporters Glut 1&4 (Cheatham et al., 1994). In 
addition, Akt activates mTOR by blocking its negative regulator TSC2, further 
promoting glycolysis (Inoki et al., 2002). However, p53 has the opposing effect as 
a tumor suppressor and has been shown to promotes oxidative phosphorylation 
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whilst inhibiting glycolysis both in vitro and in vivo (Matoba et al., 2006). This is 
achieved mainly through the transcriptional regulation of genes involved in 
glucose metabolism. p53 inhibits glycolysis by blocking the expression of glucose 
transporters Glut1 and Glut 4 (Kruiswijk et al., 2015, Zhang et al., 2013). In 
addition, p53 blocks the expression of NF-B which promotes the expression of 
Glut3 (Kawauchi et al., 2008). In some cases, p53 also activates the expression 
of Tigar which reduces the levels of phosphofructokinase-1 which is a rate-
limiting enzyme in glycolysis (Bensaad et al., 2009, Bensaad et al., 2006).  
 
To maintain oxidative phosphorylation, p53 activates the expression of a 
plethora of genes. These include Sco2 and AIF which are known to promote 
proper functioning of the electron transport chain central to oxidative 
phosphorylation (Matoba et al., 2006, Stambolsky et al., 2006). Other p53 target 
genes include Parkin which promotes the expression of pyruvate dehydrogenase 
enzyme that catalyzes some of the reactions connecting glycolysis to oxidative 
phosphorylation (Zhang et al., 2011).  The effects of Parkin on glycolysis have 
also been observed in some tumors (Cesari et al., 2003). Since oxidative 
phosphorylation is observed in quiescent tissues such as the heart and in non-
transformed cells, maintenance of oxidative phosphorylation by p53 most likely 
contribute to tumor suppression. 
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Regulation of p53 by Mdm proteins 
 
Mdm2 gene is located on chromosome 10, and was first found 
overexpressed in mouse 3T3 cells in small extra-chromosomal nuclear bodies 
called double minutes (Fakharzadeh et al., 1991). Mdm2 contains an N-terminal 
p53 interaction domain, central acidic domain, Zinc-finger domain, and C-
terminal RING domain (Figure 1.2). Mdm2 inhibits p53’s transactivation activity 
via its N-terminal hydrophobic cleft located in the p53-binding domain (Kussie et 
al., 1996, Momand et al., 1992). Mdm2 physically binds p53 and blocks 
transactivation domains from interacting with the transcriptional machinery (Chen 
et al., 1993, Oliner et al., 1993). In addition, Mdm2 also engages its C-terminal 
RING domain responsible for its E3 ubiquitin ligase activity to ubiquitinate p53 
leading to its degradation (Honda et al., 1997) .  
 
Mdm2 -/- mice exhibit embryonic lethality observed between E4.5 and E6.5 which 
is rescued by the concomitant loss of p53  (Jones et al., 1995, Montes de Oca 
Luna et al., 1995). This lethality is attributed to aberrant levels of p53-mediated 
apoptosis (Chavez-Reyes et al., 2003). These findings suggest that the chief role 
of Mdm2 during embryonic development is to restrain p53 activity. Mice 
expressing a hypomorphic allele of Mdm2 have increased p53-dependent 
apoptosis, are radiosensitive, and show defects in hematopoiesis,  indicating that 
Mdm2-mediated inhibition of p53 is required post development in adult tissues 
(Mendrysa et al., 2003). 
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Another protein known as MdmX also negatively inhibits p53 function, but 
does not trigger p53 degradation since it lacks E3 ligase activity (Linares et al., 
2003). However, MdmX heterodimerizes with Mdm2 via the RING domains and 
this enhances Mdm2-dependent ubiquitination and degradation of p53 (Linares 
et al., 2003). MdmX also shares sequence similarity with Mdm2 especially within 
the N-terminal p53-binding domain (Figure 1.2) . As such, MdmX also has the 
ability to bind p53 and blocks p53-mediated transactivation of gene expression 
(Shvarts et al., 1996). Like Mdm2-/- mice, MdmX-/- mice are embryonic lethal, 
albeit at a later developmental stage compared to Mdm2-/- mice (that is E7.5-8.5), 
and this lethality is also rescued by loss of p53 (Parant et al., 2001). This implies 
Mdm2 and MdmX possess some independent functions. Mdm2 and MdmX 
genes have p53 responsive elements and can be induced by p53. Activation of 
Figure1.2. Full-length Mdm2 and Mdmx domains. Both proteins have a 
p53 binding domain is located on the N-terminal followed by a central 
acidic domain; zinc-finger domain; and a C-terminal RING-finger domain. 
In Mdm2, the p53 binding domain if followed by followed by the NLS, 
nuclear localization signal and  NES, nuclear export signal. The numbers 
denote amino acid numbers 
p53 
binding 
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Acidic domain RING-finger domain
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both Mdm2 and MdmX by p53 demonstrates the existence of a negative 
feedback loop that restores basal p53 levels post exposure to stress. Moreover, 
both Mdm2 and MdmX are expressed at high levels in various human tumors 
indicating that these proteins are oncogenes. 
 
Some cancers do not express p53-target genes despite expressing wild 
type p53 suggesting that mechanisms that inhibit p53-mediated transcription are 
pivotal in promoting tumorigenesis. This is consistent with the observations that 
most tumors that harbor wild type p53 also have Mdm2 and MdmX gene 
amplifications (Shibagaki et al., 1995, 2008). Furthermore, some cancers do not 
harbor gene amplification, but have elevated protein levels of both Mdm2 and 
MdmX such as in retinoblastoma (Laurie et al., 2006) and melanoma 
(Gembarska et al., 2012). In sum, Mdm2- and MdmX-mediated inhibition of p53 
is critical both during development and post development in adult tissues. 
Additionally, p53 inhibition due to Mdm2 and MdmX gene amplifications or 
protein overexpression promote tumorigenesis. This implies that modifications on 
Mdm2 and/or MdmX that impede their action on p53 have the potential to delay 
tumor development and/or progression. 
 
Phosphorylation of p53  
 
Posttranslational modifications of p53 especially phosphorylation are thought 
to regulate p53 stabilization and function (Meek, 1994). In vitro, various kinases 
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have been shown to phosphorylate p53 on numerous serine and threonine 
residues within the N- and C-terminal domains (Prives, 1998). N-terminal 
phosphorylation at conserved residues like S15 (mouse S18) and S20 (mouse 
S23) were proposed to stabilize p53 by inhibiting the interaction between p53 
and Mdm2 (Appella and Anderson, 2001, Shieh et al., 1997). Both residues are 
phosphorylated following DNA damage by kinases including ATM and ATR.  In 
particular, the phosphorylation of mouse p53 at S15 by ATM promotes p53 
stabilization following DNA damage by abrogating Mdm2 inhibition of p53 in vitro 
(Shieh et al., 1997, Saito et al., 2002) . This gave rise to the idea that post 
translational modifications on residues within the p53 N-terminus that interacts 
with Mdm2 are crucial for regulating p53 activation following stress.  
 
However, loss of p53 phosphorylation on S15 mediated by ATM in mice 
(p53S18A) causes mild effects in apoptosis but does not alter p53 activation and 
stabilization along with susceptibility to tumorigenesis in mice (Toledo and Wahl, 
2006, Chao et al., 2006, Sluss et al., 2004). The phosphorylation of p53 on S23, 
was also shown to have adverse effects of p53 function in irradiated cells in vitro 
(MacPherson et al., 2004). However, p53S23A mice also displayed mild 
phenotypes (Wu et al., 2002, MacPherson et al., 2004). Double mutant 
p53S18A,S23A mice showed a more severe defect in mounting p53-dependent 
apoptosis in response to DNA damage and tumorigenesis than either p53S18A or 
p53S23A mice (Chao et al., 2006), suggesting the two phosphorylation sites have 
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synergistic functions. These studies demonstrated that post translational 
modifications on p53 TADs shown to stabilize and activate p53  in vitro do not 
fully stabilize and activate p53 in vivo (Ashcroft et al., 2000, Blattner et al., 1999). 
Therefore, it was hypothesized that post translational modifications of other 
proteins that regulate p53 function contribute to p53 activation and stabilization 
following exposure to stress in vivo. 
 
Phosphorylation of Mdm2 
 
Several phosphorylation target sites on Mdm2 have been proposed to inhibit 
or activate p53 function (Figure 1.3). ATM and Chk2 are activated in response to 
DNA damage and phosphorylate numerous serine residues on Mdm2 closer to 
the RING domain (Meek and Hupp, 2010). Rapid phosphorylation of Mdm2 by 
ATM following DNA damage result in p53 stabilization in vitro (Maya et al., 2001), 
partly by interfering with Mdm2 RING domain interactions required for Mdm2 
oligomerization and the subsequent ligase activity (Cheng et al., 2009). 
Conversely, dephosphorylation of Mdm2 by phosphatases such as Wip1 
enhances Mdm2 stability resulting in p53 ubiquitination and degradation (Lu et 
al., 2007). 
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Our lab generated Mdm2 phosphorylation site mutants to study the effects 
of ATM and c-Abl kinases on Mdm2-p53 signaling following stress. In response 
to DNA damage, ATM rapidly phosphorylates Mdm2 at S395 (mouse S394) prior 
to the accumulation of p53 in vitro (Maya et al., 2001). In response to DNA 
damage, mice expressing Mdm2 that cannot be phosphorylated at S394 
(Mdm2S394A) failed to stabilize p53, trigger p53-dependent target gene 
expression, induce cell cycle arrest, and apoptosis (Gannon et al., 2012). As a 
result, Mdm2S394A mice are resistant to the effects of ionizing radiation and also 
more susceptible to spontaneous tumorigenesis compared with controls. 
Additionally, Mdm2S394A mice have an increased susceptibility to 
lymphomagenesis induced by Eμ-myc but not by ionizing radiation (Carr et al., 
2016a), thereby demonstrating contrasting functions of Mdm2-S394 
phosphorylation in tumor suppression. Conversely, mice expressing Mdm2-S394 
phosphomimic (Mdm2S394D) exhibited prolonged p53 stabilization and activity in 
 
 
 
Figure 1.3. Proposed phosphorylation sites on hMdm2 protein sequence. 
Except for phosphorylation by Akt (S166 and S186) and CK2 (S269), all the other 
phosphorylation events have been proposed and/or reported to diminish Mdm2-
mediated p53 inhibition. Residues are  numbered like in human Mdm2 protein 
and not all phosphorylation sites are shared between humans and mice. 
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response to DNA damage, and were not susceptible to spontaneous 
tumorigenesis (Gannon et al., 2012). 
 
Another kinase that phosphorylates Mdm2 in response to DNA damage is 
c-Abl, which is phospho-activated by ATM  (Baskaran et al., 1997, Shafman et 
al., 1997). Alternatively, c-Abl can also phospho-activate ATM following DNA 
damage (Wang et al., 2011). In vitro, c-Abl phosphorylation of Mdm2 promotes 
p53 activation and stability leading to cell cycle arrest after DNA damage 
(Sawyers et al., 1994, Wen et al., 1996). Additionally, c-Abl increases p53 activity 
by reducing Mdm2-mediated degradation of p53 (Sionov et al., 1999). Moreover, 
it was shown that Mdm2-Y393 phosphorylation by c-Abl enhances p53-mediated 
gene transcription and apoptosis in cells (Goldberg et al., 2002).  
 
To explore the effects of c-Abl-mediated phosphorylation of Mdm2 on p53-
dependent responses to stress in vivo, our lab generated mice expressing Mdm2 
that cannot be phosphorylated at Y393 (Mdm2Y393F) (Carr et al., 2016b). In 
Mdm2Y393F mice, p53 stability remains unaltered following DNA damage and 
these mice are protected from bone marrow failure. However, Mdm2Y393F mice 
were susceptible to spontaneous and oncogene-induced tumorigenesis (Carr et 
al., 2016b). In double mutant Mdm2Y393F/S394A mice generated to study the impact 
of combined Mdm2-393 phosphorylation by c-Abl and Mdm2-S394 
phosphorylation by ATM, tumor latency is similar to that of Mdm2S394A mice.  
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Additionally, the response to ionizing radiation in Mdm2Y393F/S394A mice is also 
similar to that observed in Mdm2S394A mice (Carr et al., 2016b). These findings 
suggest that the phosphorylation of Mdm2 by ATM at S394 has a stronger effect 
on Mdm2-p53 signaling in response to DNA damage than Mdm2-Y393 
phosphorylation by c-Abl. These studies using double mutant mice imply no 
additive effects and this further suggests that Mdm2 phosphorylation by various 
stress-induced kinases can differentially alter the p53 response to stress.  
 
Regulation of Mdm2-p53 signaling by Akt 
 
Akt is a serine/threonine kinase and there exist three conserved isoforms 
namely Akt 1, 2, and 3. Akt signals downstream of phosphoinositide 3-kinase 
(PI3K) which is lipid kinase implicated in cellular transformation and the insulin 
response. Akt becomes fully activated by phosphorylation at T308 by PDK1(Mora 
et al., 2004, Calleja et al., 2009) and at S473 by mTORC2 (Sarbassov et al., 
2005). Activated Akt phosphorylates a myriad of substrates containing minimal 
consensus recognition motif of R-X-R-X-X-S/T-ϕ (where X is any amino acid and 
ϕ denotes a preference for large hydrophobic residues) (Alessi et al., 1996). 
These substrates include FOXO (Brunet et al., 1999), TSC2 (Potter et al., 2002), 
and GSK3 (Cross et al., 1995). Phosphorylation of proteins downstream of Akt 
generally inhibits their function, which often results in mTORC1 activation and 
enhanced cell survival, growth, metabolism, and proliferation (Georgescu, 2010). 
As such, mutations that render Akt constitutively active, such as somatic 
 
  
23 
oncogenic mutations in upstream EGFR (Ekstrand et al., 1992), HER2 (Holbro et 
al., 2003), and PIK3CA (Samuels et al., 2004), have all been implicated in 
promoting tumorigenesis. Comparably, inactivating mutations or loss-of-
heterozygosity in tumor suppressor genes such as the PI3K inhibitor PTEN, also 
promote constitutive activation of Akt (Wee et al., 2008). 
 
Transfection based studies demonstrated that Mdm2 is phosphorylated by 
Akt at S166 and S186 (mouse S163 and S183) (Mayo and Donner, 2001, 
Ogawara et al., 2002). Mdm2 phosphorylation at either residue or both enhances 
Mdm2 translocation to the nucleus. In addition, Her-2-neu overexpression 
activates Akt and this increases Mdm2-mediated p53 ubiquitination and 
degradation (Zhou et al., 2001). Moreover, Mdm2 phosphorylation by Akt inhibits 
Mdm2 auto-ubiquitination which enhances Mdm2 stability thereby promoting p53 
degradation (Feng et al., 2004). Interestingly, cancer cells harboring 
constitutively activated Akt are sensitive to Mdm2 inhibitors (Cipriano et al., 
2010). Therefore, understanding the effects of Mdm2 phosphorylation by Akt 
under physiological conditions is crucial, especially in the context of tumor cell 
signaling. 
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Aims of this dissertation 
 
In this dissertation I will present the work I performed investigating the 
physiological significance of Mdm2 phosphorylation by Akt in vivo. To this end, I 
generated two Mdm2 mutant mouse models that cannot be selectively 
phosphorylated at S163 and S183 on both Mdm2 alleles (Mdm2S163A and 
Mdm2S183A respectively). Since Mdm2 phosphorylation by Akt reduced Mdm2-
mediated inhibition of p53 (Zhou et al., 2001, Mayo and Donner, 2001, Feng et 
al., 2004), I hypothesized that Mdm2S163A and Mdm2S183A mice will express 
elevated levels of p53, and similar to Mdm2-/- mice, will therefore exhibit 
developmental defects and/or embryonic lethality. As such, my first aim in this 
dissertation was to examine how Mdm2 phosphorylation by Akt affects 
development. 
 
Well established functions of p53 in response to stress include the induction 
of cell cycle arrest, senescence, and apoptosis. For that reason, the second aim 
of this dissertation was to study whether Akt phosphorylation of Mdm2 at 
endogenous levels alters cell growth and proliferation following exposure to 
plating stress and DNA damage. To this end, I utilized Mdm2S163A and Mdm2S183A 
mouse embryonic fibroblasts (MEFs) to examine the effects on cell proliferation 
and p53-mediated DNA damage responses in vitro. Since Mdm2S183A MEFs 
displayed most overt phenotype under conventional cell culture conditions, I then 
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focused on exploring the effects of only Mdm2-S183 phosphorylation on DNA 
damage responses.  
 
My third aim was to determine the impact Mdm2-S183 phosphorylation by 
Akt has on tumor suppression in vivo. I utilized three different mouse models to 
look at (i) DEN-induced liver cancer, (ii) DMBA/TPA-induced skin cancer, and (iii) 
lung cancer caused by the expression of oncogenic K-ras.  With these models, I 
examined how Mdm2-S183 affects p53-dependent mechanisms known to 
mediate tumor suppression.  
 
Lastly, my fourth aim was to investigate how Mdm2-S183 phosphorylation 
affects glucose metabolism. As mentioned previously, mice that fail to induce 
canonical p53 tumor suppressor functions are still able to properly regulate 
various aspects metabolism. Therefore, it is plausible that p53-dependent 
alterations in glucose metabolism may contribute to tumor suppression. To this 
end, I employed both in vitro and in vivo assays to examine whether Mdm2S183A 
mice exhibited altered glucose metabolism compared with Mdm2WT mice. 
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Introduction 
 
Mdm2-/- mice are embryonic lethal around E4.5-E6.5, and this lethality is 
rescued by loss of p53 (Jones et al., 1995, Montes de Oca Luna et al., 1995). 
This is unlike p53-/- mice which develop normally into adulthood but are more 
susceptible to tumorigenesis (Donehower et al., 1992). Cultured Mdm2-/- embryos 
show evidence of apoptosis (Chavez-Reyes et al., 2003), suggesting that loss 
Mdm2-mediated inhibition of p53 is necessary during mouse development. Since 
Mdm2 S163 and/or S183 phosphorylation by Akt reduces p53 activity in 
transfection based assays, I explored whether at endogenous levels, Mdm2-
S183 and -S163 affects mouse development. I found that Mdm2S163A and 
Mdm2S183A mice are viable, fertile, and obtained at Mendelian ratios. In addition, I 
also show that unchallenged Mdm2S163A and Mdm2S183A mice are phenotypically 
indistinguishable from Mdm2WT mice. These findings show that Mdm2 
phosphorylation at S163 or S183 is not required for development in mice. 
 
I also postulated that loss of Mdm2-S163 and -S183 phosphorylation by 
Akt at physiological levels increases p53 levels and activity. As a result, 
Mdm2S183A and Mdm2S183A MEFs will display altered p53 function following 
exposure to plating stress and DNA damage. I will show that Mdm2S183A MEFs, 
but not Mdm2S163A MEFs, failed to proliferate due to premature senescence. 
Mdm2S183A MEFs also expressed higher levels of p53 and p53-target genes 
when cultured at high oxygen and these phenotypes were reversed at low 
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oxygen. Furthermore, I will demonstrate that Mdm2-S183 phosphorylation at 
endogenous levels enhanced Mdm2 nuclear localization and stability, and 
lowered p53 levels. These results are consistent with what was observed in 
studies using transfection-based assays. To my knowledge, this is the first time 
showing that phosphorylation of Mdm2-S183 by Akt endogenous protect cells 
from p53-mediated senescence induced by oxidative stress.  
 
Mdm2 phosphorylation by different DNA damage-induced kinases dictate 
the type of p53-dependent responses (Gannon et al., 2012b, Carr et al., 2016b). 
Therefore, I explored whether Mdm2-S183 phosphorylation by Akt affects p53-
dependent DNA damage response. In this chapter, I will demonstrate that Mdm2-
S183 phosphorylation does not alter p53 activation and stabilization following 
acute genotoxic stress. Additionally, Mdm2-S183 phosphorylation does not 
impact p53-mediated cell arrest in vitro after treatment with various DNA 
damage-inducing agents. Furthermore, Mdm2 phosphorylation by Akt does not 
alter p53-dependent radiosensitivity and DNA-damage induced apoptosis in vivo. 
My data indicates that the phosphorylation of Mdm2 does not control p53-
mediated responses to DNA damage in vitro and in vivo. 
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Results 
 
To generate mice expressing Mdm2 that cannot be phosphorylated at 
S163 and S183, pseudopregnant mice received manipulated blastocysts from 
zygotes injected with Cas9 mRNA, gRNAs with complementary sequences to 
regions harboring S163 and S183 residues, and 100mer oligonucleotides in 
which S163 or S183 are substituted with alanine residues (Figure 2.1a and b). 
Substituting S163 and S183 with alanine residues also introduced new restriction 
enzyme cut sites (Figure 2.1b). Therefore, to confirm germline transmission of 
the intended missense mutations in the Mdm2 sequence, genomic DNA flanking 
the S163 and S183 was amplified using PCR followed by restriction enzyme 
digestion with BsrdI for S163A mice and ApaI for S183A mice (Figure 2.1b and 
c). Progeny from heterozygous Mdm2S163A and Mdm2S183A intercrosses were 
obtained at Mendelian ratios (Figure 2.2e), and male and female progeny were 
recovered at similar frequencies. In addition, homozygous Mdm2S163A and 
Mdm2S183A mice were viable and fertile. Furthermore, DNA sequencing confirmed 
the presence of the intended mutations and absence of off target mutations in the 
Mdm2 sequence (Figure 2.1e). Importantly, Mdm2S163A and Mdm2S183A mice 
were backcrossed to wild type mice for six and nine generations respectively, in 
an effort to get rid of potential off target mutations. Taken together, this data 
shows that Mdm2-S163 and -S183 phosphorylation is not required for 
development in mice. 
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Figure 2.1. Mdm2-S163 and -S183 phosphorylation is dispensable for 
development. (A) Schematic representation of the CRISPR-Cas9 based method 
used to generate of Mdm2
S163A
 and Mdm2
S183A
 mice. (B) Sequences of WT and 
mutant alleles for Mdm2 codon 163 and 183 (C) Agarose gel electrophoresis 
image showing BsrDI digestion of DNA amplified by PCR using primers flanking 
the 163 codon of Mdm2. (D) Agarose gel electrophoresis image showing ApaI 
digestion of DNA amplified by PCR using primers flanking Mdm2 183 codon. (E) 
Numbers of progeny from heterozygous intercrosses for both Mdm2
S163A
 and 
Mdm2
S183A
 alleles. (F) Sequencing of Mdm2 DNA regions harboring Mdm2 S163 
and S183 codons. (G) Weight comparison between unchallenged Mdm2WT 
(n=16), Mdm2S163A (n=15) and  Mdm2S183A (n=16) mice. (H) Survival of Mdm2WT 
(n=11) and Mdm2S183A mice (n=14). 
 
Loss of Mdm2 function in the skin in mice results in elevated levels of p53 
and this triggers premature aging in the epidermis (Gannon et al., 2011). 
Additionally, mice with chronically higher levels of p53 show signs of premature 
aging whilst being less susceptible to tumorigenesis (Tyner et al., 2002). In 
contrast, several transgenic mice with higher levels of p53 do not show signs of 
premature aging, but are resistant to tumorigenesis similar to the aging prone 
models (Garcia-Cao et al., 2002, Matheu et al., 2007). This suggests that p53’s 
role in aging is influenced by the genetic background of these mice.  
 
Next, I tested whether loss of Akt-dependent phosphorylation of Mdm2 
may induce signs of premature aging such as weight loss and shortened 
lifespan, possibly due to elevated p53. However, unchallenged Mdm2S163A and 
Mdm2S183A mice weights were comparable to Mdm2WT mice (Figure 2.1g). 
Additionally, there was no significant difference between the survival of Mdm2WT 
and that of Mdm2S183A mice (Figure 2.1h). This suggests that phosphorylation of 
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Mdm2 by Akt at S183 does not promote premature aging or alter longevity in 
unchallenged mice. Mdm2S163A and Mdm2S183A mice did not phenocopy Mdm2-/- 
mice. Therefore, it is possible that p53 levels and activity in unchallenged 
Mdm2WT and Mdm2S183A mice may not be significantly different.  
 
  Next, I examined whether phosphorylation of Mdm2-S163 and -S183 
alters cell proliferation. To this end, I used early passage MEFs generated from 
Mdm2
S163A
 and Mdm2
S183A
 mice and performed cell growth and proliferation 
assays. Surprisingly, Mdm2S183A MEFs significantly failed to proliferate compared 
with Mdm2WT, Mdm2S163A, and p53-/- MEFs (Figure 2.2a). Additionally, Mdm2S183A 
MEFs failed to form colonies following low-density stress plating (Figure 2.2 b). 
Intriguingly, Mdm2S183A MEFs displayed salient features of senescence which 
include the apparent cessation of cell growth in culture and flattened morphology. 
I therefore stained MEFs for senescence-associated β-galactosidase and the 
amount of cells that stained positive for senescence-associated β-galactosidase 
were significantly higher in Mdm2S183A MEFs compared with Mdm2WT, 
Mdm2S163A, and p53-/- MEFs (Figure 2.2c). Since these MEFs were passage 3 
and Mdm2WT MEFs enters replicative senescence after about 6 passages 
(Groisman et al., 2006), this data demonstrated that Mdm2S183A MEFs were prone 
to premature senescence. 
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Figure 2.2. Mdm2 S183 phosphorylation is required for cell proliferation  
(A) Proliferation of passage 3 Mdm2
WT
, Mdm2
S163A
, Mdm2
S183A
, and p53
-/- 
mouse 
embryonic fibroblasts cultured at 21% oxygen. Student’s T test **p<0.01 (n=3). 
(B) Representative images for colony formation assay (left) and colony 
quantification (right) performed using passage 2 Mdm2
WT
, Mdm2
S163A
, 
Mdm2
S183A
, and p53
-/- 
embryonic fibroblasts. Data is expressed as mean ± 
standard deviation. Student’s T test **p<0.01 (n=3). (C) Representative images 
showing results for senescence-associated β-galactosidase staining (left) and 
quantification (right) of positively stained passage 3 Mdm2
WT
, Mdm2
S163A
, 
Mdm2
S183A
, and p53
-/- 
mouse embryonic fibroblasts cultured at 21% oxygen. Data 
is expressed as mean ± standard deviation. Student’s T test *p<0.05 and 
**p<0.01 (n=3). (D) Flow cytometry analyses (left) and quantification of apoptotic 
cells (right) using Annexin V and propidium iodide staining in passage 3 Mdm2
WT
, 
Mdm2
S163A
 Mdm2
S183A
, and p53
-/-
 mouse embryonic fibroblasts cultured at 21% 
oxygen. Data is expressed as mean ± standard deviation. Student’s T test 
**p<0.01 (n=3). 
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Wild type MEFs are generally resistant to apoptosis and often undergo 
p53-mediated G1 arrest when exposed to stress like DNA damage (Kastan et al., 
1992). However, expression of adenovirus E1A oncoprotein, c-Myc, and E2F1 
can trigger p53-mediated apoptosis in wild type MEFs following DNA damage 
(Hermeking and Eick, 1994, Debbas and White, 1993, Qin et al., 1994). Although 
unlikely, I explored the possibility that Mdm2S183A MEFs were failing to proliferate 
partly due to apoptosis triggered by plating stress. Annexin V/PI staining showed 
that the percentage of apoptotic cells in Mdm2S183A MEFs was not significantly 
different to that in Mdm2WT and Mdm2S163A MEFs (Figure 2.2d), suggesting that 
the observed proliferation defect in Mdm2S183A MEFs is not due to apoptosis. 
 
Senescence can be triggered by oncogene overexpression, telomere 
erosion, DNA damage from reactive oxygen species, and inflammation (McHugh 
and Gil, 2018). Since mice have long telomeres and MEFs used here were not 
transduced with oncogenes, I posited that Mdm2S183A MEFs were senescent due 
to oxidative stress. I cultured Mdm2
WT
, Mdm2
S183A
, and p53
-/-
 MEFs under low 
oxygen conditions (5% oxygen) in the presence of a reactive oxygen species 
scavenger N-acetyl cysteine (NAC). Proliferation and colony formation defects 
observed in Mdm2
S183A MEFs cultured at ~21% oxygen were rescued by culturing 
these MEFs at low oxygen (Figure 2.3a-b).  
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Figure 2.3. Normoxic conditions rescue Mdm2S183A MEFs from senescence 
(A) Proliferation of passage 3 Mdm2
WT
, Mdm2
S183A
, and p53
-/- 
mouse embryonic 
fibroblasts cultured at 5% oxygen in media supplemented with 5mM N-acetyl 
cysteine. Student’s T test **p<0.01 (n=3). (B) Representative images for colony 
formation assay (left) and Colony quantification (right) of passage 2 Mdm2
WT
, 
Mdm2
S183A
, and p53
-/- 
mouse embryonic fibroblasts cultured at 5% oxygen in 
media supplemented with 5mM N-acetyl cysteine. Data is expressed as mean ± 
standard deviation. Student’s T test *p<0.05 and **p<0.01 (n=3). (C) Staining for 
senescence-associated β-galactosidase (left) and quantification (right) of 
positively stained Mdm2
WT
, Mdm2
S183A
 , and p53
-/- 
mouse embryonic fibroblasts 
cultured at 5% oxygen in media supplemented with 5mM N-acetyl cysteine. Data 
is expressed as mean ± standard deviation. Student’s T test **p<0.01 (n=3). 
(D)Flow cytometry analyses (left) and quantification of apoptotic cells (right) 
using Annexin V and Propidium iodide staining in passage 3 Mdm2
WT
, 
Mdm2
S183A
, and p53
-/-
 mouse embryonic fibroblasts cultured at 5% oxygen in 
media supplemented with 5mM N-acetyl cysteine. Data is expressed as mean ± 
standard deviation. Student’s T test *p<0.05 (n=3). 
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In addition, culturing Mdm2S183A MEFs at low oxygen also reduced amount 
of premature senescent cells by about 40% of what was observed at high oxygen 
(Figure 2.3c). There was no significant difference in the percentage of apoptotic 
cells in Mdm2WT and Mdm2S183A MEFs cultured at low oxygen MEFs (Figure 
2.3d). Therefore, the rescue of proliferation defects in Mdm2S183A MEFs by low 
oxygen culture indicates that Mdm2 phosphorylation at S183 prevents premature 
senescence in the presence of oxidative stress.  
 
Next, I performed a 2’,7’-dichlorofluorescin diacetate (DCFDA) staining 
assay to test whether Mdm2S183A MEFs had higher levels of intracellular ROS 
when cultured under high oxygen compared to low oxygen (Figure 2.4a). DCFDA 
is a cell-permeant and fluorogenic dye used to determine the amount of hydroxyl, 
peroxyl and other reactive oxygen species (ROS) in the cell. Both at high and low 
oxygen, the levels of ROS in Mdm2S183A MEFs were similar to those in Mdm2WT 
MEFs and p53-/- MEFs (Figure 2.4a). This indicates that the proliferation defect 
observed in Mdm2S183A MEFs cultured at high oxygen is not due to increased 
production of ROS.  
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Figure 2.4. Mdm2S183A MEFs are sensitive to oxidative stress. 
(A) Flow cytometry analyses (left) and quantification of DCF staining (right) in 
passage 3 Mdm2
WT
, Mdm2
S183A
, and p53
-/-
 MEFs cultured at 21% oxygen and 
5% oxygen in media supplemented with NAC. Data is expressed as mean 
fluorescence ± standard deviation. Student’s T test **p<0.01 (n=3). (B) Lipid 
peroxidation assay measuring the quantity of MDA normalized to protein 
concentration for high and low oxygen passage 3 MEFs. Data is expressed as 
mean ± standard deviation. Student’s T test *p<0.05 and **p<0.01 (n=3). (C) 
Immunofluorescence staining for 8-Oxo-2'-deoxyguanosine in passage 3 
Mdm2
WT
 and Mdm2
S183A
 MEFs cultured either at 21% oxygen (left ) or 5% 
oxygen (right) in media supplemented with NAC. Scale bar = 10μm.  
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Since the amount of ROS is similar between Mdm2WT and Mdm2S183A 
MEFs, it is possible that Mdm2S183A MEFs are sensitive to the levels of oxidative 
stress present in culture at high oxygen. Exposure to high levels of oxidative 
stress can cause damage to lipids and DNA in cells with compromised oxidative 
stress responses. Therefore I, quantified the amount of the lipid peroxidation by-
product malondialdehyde (MDA) to determine whether Mdm2S183A MEFs are 
more susceptible to lipid peroxidation compared with Mdm2WT MEFs. The 
amount of MDA in Mdm2S183A MEFs was significantly higher than in Mdm2WTand 
p53-/- MEFs (Figure 2.4b). Additionally, the amount of 8-Oxo-2-deoxyguanosine, 
which is a marker of DNA damage induced by oxidative stress, was significantly 
elevated in Mdm2S183A MEFs compared with Mdm2WT MEFs (Figure 2.4c). These 
findings suggest that loss of Mdm2-S183 phosphorylation compromises oxidative 
stress responses in MEFs and sensitizes them to oxidative stress. 
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Figure 2.5. Mdm2-S183 phosphorylation prevents premature senescence in 
MEFs (A) Western blot analyses (left) and quantification of protein levels (right) in 
passage 3 Mdm2
WT
, Mdm2
S183A
, and p53
-/- 
mouse embryonic fibroblasts cultured 
at 21% oxygen. Data is expressed as mean ± standard deviation. Student’s T 
test **p<0.01(n=3). (B) Western blot analyses (left) and quantification of protein 
levels in (right) passage 3 Mdm2
WT
, Mdm2
S183A
, and p53
-/- 
mouse embryonic 
fibroblasts cultured at 5% oxygen in media supplemented with 5mM N-acetyl 
cysteine. Data is expressed as mean ± standard deviation. Student’s T test 
*p<0.05 and **p<0.01 (n=3).  
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Phosphorylation of Mdm2 at S163 and/or S183 enhances Mdm2-mediated 
degradation of p53 in overexpression studies (Zhou et al., 2001, Mayo and 
Donner, 2001). To determine whether p53 levels are altered in Mdm2S183A MEFs, 
I performed western blot analysis using protein lysates extracted from MEFs 
cultured at either low and high oxygen. At high oxygen, the levels of p53 and 
activated p53 protein were significantly elevated in Mdm2S183A MEFs compared 
with Mdm2WT MEFs (Figure 2.5a). In contrast, Mdm2 protein levels were 
significantly lower in Mdm2S183A MEFs compared to Mdm2WT MEFs cultured at 
high oxygen. This suggests that phosphorylation of Mdm2 at S183 increases 
Mdm2 stability and degradation of p53 in the presence of oxidative stress. 
 
In MEFs cultured at low oxygen in the presence of ROS scavenger N-
acetyl cysteine, p53 and activated p53 (p-p53 (S18)) protein levels where still 
significantly higher in Mdm2S183A than in Mdm2WT MEFs (Figure 2.5b). However, 
the differences in levels of p53 and p-p53 (S18) between Mdm2WT and 
Mdm2S183A was significantly smaller at low oxygen compared to high oxygen, 
about 2-fold for p53 protein at low oxygen compared to 6-fold difference at high 
oxygen. The same trend was observed for activated p53. Additionally, Mdm2 
protein levels were also still significantly higher in Mdm2WT MEFs than in 
Mdm2S183A MEFs, with this difference being more pronounced at high oxygen 
than at low oxygen as well. These results indicate that the effects of Mdm2-S183 
phosphorylation on p53 expression and activation are diminished at low oxygen. 
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p21 is known to mediate p53-dependent senescence (Macleod et al., 
1995). As a result, p21 protein and mRNA expression are often used as markers 
for of p53-mediated senescence. Another frequently used senescence marker is 
the CDK4/6 inhibitor p16. In high oxygen MEFs, both p21 and p16 protein levels 
were significantly elevated in Mdm2S183A MEFs than in Mdm2WT MEFs (Figure 
2.5a). However, at low oxygen, there was a significant difference in p21 protein 
levels, but not p16,  between Mdm2WT and Mdm2S183A MEFs (Figure 2.5b).  
These results suggest that phosphorylation of Mdm2-S183 prevents premature 
senescence likely mediated by p53 in early passage MEFS cultured at high 
oxygen.  
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Figure 2.6. Mdm2-S183 phosphorylation alters the expression of p53-target 
genes that mediate senescence. (A) Relative mRNA expression levels for 
genes known to mediate senescence in passage 3 Mdm2
WT
, Mdm2
S183A
, and 
p53
-/- 
mouse embryonic fibroblasts cultured at 21% oxygen. Data is expressed as 
mean ± standard deviation. Student’s T test **p<0.01 (n=3). (B) Relative mRNA 
expression levels for genes known to mediate senescence in passage 3 
Mdm2
WT
, Mdm2
S183A
, and p53
-/- 
mouse embryonic fibroblasts cultured at 5% 
oxygen in media supplemented with 5mM N-acetyl cysteine. Data is expressed 
as mean ± standard deviation. Student’s T test *p<0.05 and **p<0.01 (n=3). 
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In addition to p21 and p16, several other genes controlled by p53 such as 
Sestrins and Pai-1  can mediate senescence. Therefore, I performed RT-qPCR 
to quantify the mRNA levels of these genes in low and high oxygen MEFs. At 
high oxygen, Mdm2S183A MEFs expressed significantly higher levels of p21, Pai-
1, and Pai-2 genes than Mdm2WT MEFs (Figure 2.6a). At low oxygen, there were 
no significant differences in the mRNA levels of senescence-mediating genes in 
Mdm2WT and Mdm2S183A MEFs (Figure 2.6b). These results further support a role 
for Mdm2 phosphorylation at S183 in preventing p53-mediated premature 
senescence by inhibiting the induction of a subset of p53-target genes that 
mediate senescence. 
 
Mdm2 phosphorylation by Akt enhances Mdm2 translocation to the 
nucleus and enhance p53 degradation in overexpression studies (Mayo and 
Donner, 2001, Zhang et al., 2018). Therefore, I performed western blot analysis 
using low oxygen MEFs stimulated with IGF-1 to determine whether 
phosphorylation of endogenous Mdm2 by Akt alters Mdm2-p53 signaling (Figure 
2.7). In both Mdm2WT and Mdm2S183A MEFs, stimulation with IGF-1 activated Akt 
as shown by the increase in Akt S473 and T308 phosphorylation (Figure 2.7a-b). 
In Mdm2WT MEFs, activation of Akt led to a reduction in p53 levels which was 
accompanied by an increase in Mdm2 levels (Figure 2.7a). In contrast, activation 
of Akt did not alter p53 levels in Mdm2S183A MEFs which remained elevated whilst 
Mdm2 levels declined. These findings suggest that activation of Akt enhanced 
Mdm2 stability and promotes degradation of p53. 
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Figure 2.7. Mdm2-S183 phosphorylation by Akt promotes Mdm2 stability 
and 53 degradation. (A) Western blot analyses for passage 2 Mdm2
WT 
embryonic fibroblasts cultured at 5% oxygen with N-acetyl cysteine. Cells were 
either left untreated, or nutrient starved for 3 hours and stimulated with 150ng/ml 
IGF-1 followed by protein extraction at the indicated time points. Triple knockout 
cells (TKO) are deficient for Mdm2, MdmX, and p53. (B) Western blot analyses 
for passage 2 Mdm2
S183A 
mouse embryonic fibroblasts cultured at 5% oxygen 
with N-acetyl cysteine. Cells were either left untreated, or nutrient starved for 3 
hours and stimulated with 150ng/ml IGF-1 followed by protein extraction at the 
indicated time points. Triple knockout cells (TKO) are deficient for Mdm2, MdmX, 
and p53.  
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To determine whether activation of Akt alters the localization of Mdm2 and 
affects p53 levels, I performed western blots on nuclear and cytoplasmic protein 
lysates extracted from MEFs cultured at low oxygen and stimulated with IGF-1 
for 2 hours (Figure 2.8). Mdm2 protein levels were significantly higher in the 
nucleus of Mdm2WT MEFs than in Mdm2S183A MEFs (Figure 2.8a), indicating that 
Akt activation promotes Mdm2 nuclear localization at endogenous levels. 
Additionally, stimulation of IGF-1 reduced p53 protein levels in the nucleus in 
Mdm2WT MEFs but not in Mdm2S183A MEFs. These findings demonstrate that 
Mdm2-S183 phosphorylation by Akt at endogenous levels promotes Mdm2 
nuclear localization and p53 degradation.  
 
To confirm that Akt phosphorylates Mdm2, alter Mdm2 localization and 
affect p53 levels, I blocked Akt activation using the Akt inhibitor MK-2206 and 
repeated the western analyses in figure 2.8a. There was no significant difference 
between the nuclear Mdm2 protein levels in Mdm2WT MEFs and Mdm2S183A 
MEFs (Figure 2.8b). This suggests that inhibition of Akt activation, which I infer to 
block Mdm2-S183 phosphorylation, diminishes Mdm2 nuclear translocation. 
Furthermore, the levels of nuclear p53 in Mdm2WT MEFs was comparable to 
those in Mdm2S183A MEFs, implying that Akt-mediated phosphorylation of Mdm2-
S183 enhances Mdm2-dependent degradation of p53 in Mdm2WT MEFs.  
 
 
 
  
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8. Mdm2-S183 phosphorylation by Akt promotes Mdm2 nuclear 
localization and p53 degradation. (A) Western blot analyses (left) and 
quantification of protein levels (right) for nuclear and cytoplasmic proteins 
extracted 2 hours post IGF-1 treatment from passage 2 Mdm2
WT
 and Mdm2
S183A 
mouse embryonic fibroblasts cultured at 5% oxygen with N-acetyl cysteine. 
Student’s T test *p<0.05 and **p<0.01 (n=3). (B) Western blot analyses (left) and 
quantification of protein levels (right) for nuclear and cytoplasmic proteins 
extracted 2 hours post IGF-1 treatment  in the presence of an Akt inhibitor MK-
2206 (5 μM) from passage 2 Mdm2
WT
 and  Mdm2
S183A 
mouse embryonic 
fibroblasts cultured at 5% oxygen with N-acetyl cysteine. Student’s T test *p<0.05 
and **p<0.01 (n=3). 
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Having established that Akt activation can affect Mdm2-p53 signaling at 
endogenous levels, next, I explored whether Mdm2 S183 phosphorylation 
influences DNA damage responses mediated by p53. Exposure to DNA damage 
inducing agents such as ionizing radiation activates and stabilizes p53, which is a 
critical effector of DNA damage responses which include DNA repair and cell 
cycle arrest (Williams and Schumacher, 2016). As expected, p53 and activated 
p53 protein levels were elevated in low oxygen Mdm2WT and Mdm2S183A MEFs 
following treatment with  4Gy of ionizing radiation (Figure 2.9a). However, there 
was no significant difference in the levels of p53 and activated p53 protein in 
Mdm2WT and Mdm2S183A MEFs (Figure 2.9a and b). This  data demonstrated that 
Mdm2 S183 phosphorylation does not affect p53 activation and stabilization 
following DNA damage. 
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Figure 2.9. Phosphorylation of Mdm2 at S183 does not affect p53 activation 
and stabilization after DNA damage. (A) Western analyses of protein lysates 
collected from passage 2 Mdm2
WT
 and Mdm2
S183A
 MEFs cultured at 5% oxygen 
in NAC supplemented media and treated with 4Gy IR for the indicated time 
points. Triple knockout cells (TKO) are deficient for Mdm2, MdmX, and p53. (B) 
Quantification of p53 and p-p53 (S18) relative to the loading control protein 
vinculin for westerns in (A). Data is expressed as mean ± standard deviation. 
Student’s T test *p<0.05 and **p<0.01 (n=3). 
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To examine DNA damage-induced cell cycle arrest, which is also 
mediated by p53, I performed cell cycle analysis on low oxygen MEFs treated 
with various DNA damage inducing agents (Figure 2.10). The percentage of cells 
in S phase was not significantly different between Mdm2WT and Mdm2S183A MEFs 
treated with ionizing radiation, etoposide, and doxorubicin (Figure 2.10a). As 
expected, p53-/- MEFs failed to undergo cell cycle arrest after DNA damage. This 
data suggests that Mdm2-S183 phosphorylation does not influence DNA 
damage-induced cell cycle arrest mediated by p53. 
 
 Mice exposed to acute ionizing radiation succumb to bone marrow failure 
(Gudkov and Komarova, 2003) (Komarova et al., 2004). This is mediated by p53-
dependent apoptosis in bone marrow and other radiosensitive tissues such as 
the spleen and thymus. p53-/- mice do not succumb to hematopoietic failure since 
the cells are resistant to apoptosis. To determine whether Mdm2 phosphorylation 
will affect p53-mediated DNA damage responses in vivo, cohorts of Mdm2WT and 
Mdm2S183A mice were treated with a sublethal dose of ionizing radiation (7.5Gy) 
and monitored for survival. There was no significant difference in survival 
between Mdm2WT and Mdm2S183A mice (Figure 2.11a), suggesting that Mdm2-
S183 phosphorylation does not influence sensitivity to ionizing radiation in mice. 
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Figure 2.10. Phosphorylation of Mdm2 at S183 does not alter p53-mediated 
cell cycle arrest induced by DNA damage in vitro.  
(A) Representative flow cytometry results for cell cycle analyses (top panel) in 
Mdm2
WT
, Mdm2
S183A
, and p53
-/-
 MEFs cultured at 5 % oxygen with NAC and 
exposed to the indicated DNA damaging agents and pulsed with BrdU and 
stained with PI. (B) The % of cells in S phase is quantified (bottom panel) and 
presented as mean ± standard deviation. Student’s T test *p<0.05 and **p<0.01 
(n=3). 
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To ascertain whether Akt-mediated phosphorylation of Mdm2 affects 
apoptosis in radiosensitive tissues following exposure to ionizing radiation , I 
performed TUNEL staining on spleen and thymus tissues harvested from 
Mdm2WT and Mdm2S183A mice following exposure to ionizing radiation (5Gy). 
There was no difference in the amount of apoptosis in spleen and thymus of 
Mdm2WT mice compared with Mdm2S183A  mice (Figure 2.11b). Therefore, 
phosphorylation of Mdm2 by Akt at S183 is not required for mediating p53-
dependent DNA damage responses in vivo in mice. 
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Figure 2.11. Phosphorylation of Mdm2 at S183 does not affect DNA damage 
responses in vivo. (A) Survival of Mdm2
WT
 (n=9)and Mdm2
S183A
 (n=15)mice 
treated with a sub lethal dose of ionizing radiation (7.5Gy). (B) TUNEL staining of 
thymus and spleen harvested from Mdm2
WT
 and Mdm2
S183A 
mice 2 hours after 
treatment with ionizing radiation (5Gy). Scale bars are 200 µm. 
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 CHAPTER III: MDM2-S183 PHOSPHORYLATION BY AKT PROMOTES 
TUMORIGENESIS INDUCED BY CARCINOGEN EXPOSURE AND 
ONCOGENE EXPRESSION 
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Introduction 
 
p53 deficient mice develop highly penetrant spontaneous tumors, 
underscoring the role of p53 as a potent tumor suppressor protein (Donehower et 
al., 1992). Post translational modifications on Mdm2 such as phosphorylation of 
S394 by ATM and S393 by c-Abl, have an impact on p53-dependent tumor 
suppression. For instance, Mdm2S394A mice are more susceptible to Eμ-myc-
driven lymphomagenesis and spontaneous tumorigenesis, but less susceptible to 
lymphomas induced by ionizing radiation compared to Mdm2WT mice (Gannon et 
al., 2012a, Carr et al., 2016a).  Additionally, Mdm2Y393F mice are more 
susceptible to spontaneous and oncogene-induced tumorigenesis (Carr et al., 
2016c). However, Mdm2S394A/Y393F mice develop spontaneous tumors at a 
frequency similar to that observed in Mdm2S394A mice, thereby suggesting that 
ATM phosphorylation of Mdm2 plays a more prominent role and there are no 
synergistic effects on tumor suppression. 
 
In chapter II, I established that phosphorylation of endogenous Mdm2 at 
S183 by Akt increases Mdm2 stability and Mdm2 nuclear localization. As a result,  
p53 levels and activity are reduced and this protects cells from p53-dependent 
premature senescence induced by oxidative stress. However, Mdm2-S183 
phosphorylation does not mediate p53-dependent DNA damage response in vitro 
and in vivo. To explore whether Mdm2 phosphorylation at S183 affects aspects 
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of p53-mediated tumor suppression, I utilized three different mouse models in 
which oxidative stress plays a critical role in promoting tumorigenesis. 
 
First, I explored the role of Mdm2-S183 phosphorylation in tumorigenesis 
utilizing the carcinogen diethylnitrosamine (DEN) to induce liver cancer. 
Biotransformation of DEN produces DNA alkylating metabolites resulting in 
damage to various macromolecules which contribute to hepatocarcinogenesis 
(Verna et al., 1996). DEN also triggers the accumulation of ROS which causes 
DNA alkylation, lipid peroxidation, and protein oxidation, necessary for 
hepatocarcinogenesis (Sanchez-Perez et al., 2005, Cerutti et al., 1994). Infant 
mice express high levels of DEN alkylating enzymes, with males having higher 
and more prolonged expression than females, and therefore more susceptible to 
DEN-induced carcinogenesis (Rao and Vesselinovitch, 1973). Development of 
hepatocellular carcinoma (HCC)  is also prevalent in males in both humans and 
rodents. DEN induces HCC in about 100% of male mice compared to about 30% 
in female mice (Nakatani et al., 2001, Li et al., 2012). This gender disparity in 
HCC formation is partly due to estrogen-mediated inhibition of IL-6 production  in 
females but not in males (Naugler et al., 2007). IL-6 regulates hepatic responses 
to systemic inflammation and promotes hepatocyte proliferation (Cressman et al., 
1996). Accordingly, this sexual dimorphism in DEN-induced liver cancer is 
abolished in IL-6 knockout mice (Naugler et al., 2007).  In addition, androgen 
signaling in males activates Foxa1/2-mediated biosynthesis and replication of 
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DNA and cell proliferation in male mice, whilst these processes are inhibited by 
estrogen in female mice (Li et al., 2012). Intriguingly, loss of Foxa1/2 reverses 
the gender dimorphism in DEN-induced hepatocarcinogenesis, further supporting 
the notion that sexual differences in susceptibility to HCC are primarily driven by 
sex-dependent hormonal signaling pathways. Therefore, I administered DEN 
only in infant male mice for my liver cancer studies in order to obtain more 
consistent results unconfounded by sexual differences.  
 
The administration of DEN activates p53 in hepatocytes and mesenchymal 
cells (Lim, 2002), and this is thought to promote the clearance of damaged cells. 
DEN-treated mice with conditional deletion of p53 in hepatic stellate cells (HSC-
p53Δ/Δ) developed more tumors compared with controls (Lujambio et al., 2013).  
HSC-p53+/+ mice displayed p53-driven senescence-associated secretory 
phenotype (SASP) which triggered macrophages to an antitumorigenic M1 fate. 
In contrast, HSC-p53Δ/Δ mice polarized macrophages towards a pro-tumorigenic 
M2 phenotype which enhanced the clearance of senescent HSCs and enhanced 
cell proliferation. This suggests that p53 expression in the liver promotes 
senescence to suppress DEN-induced liver tumorigenesis. Here, I will discuss 
my findings showing that phosphorylation of Mdm2-S183 promotes DEN-induced 
liver tumorigenesis in mice, partly through the inhibition of p53-dependent 
senescence.  
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Secondly, I took advantage of the well-established 7,12-dimethylbenz[a]-
anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-driven cancer 
model to explore the role of Mdm2-S183 phosphorylation in carcinogen-induced 
skin tumorigenesis. Single application of the carcinogen DMBA causes mutations 
in several genes in keratinocyte stem cells in the bulge region of hair follicles, 
with H-ras being the most prominent DMBA target followed by K-ras (Ise et al., 
2000, Brown et al., 1990, Morris, 2004). Two-weeks after the initiating dose of 
DMBA, tumor formation is promoted by the twice-weekly application of TPA. This 
promotion step using TPA triggers epidermal hyperplasia and selective clonal 
expansion of the mutant stem cells (Karen et al., 1999, Hennings et al., 1987). 
Additionally, TPA treatment also triggers the generation of ROS which causes 
oxidative damage and inflammation (Perchellet and Perchellet, 1989, Nakamura 
et al., 1999). Furthermore, TPA treatment also leads to additional genetic lesions 
and aneuploidy (Abel et al., 2009). Moreover, tumor promotion with TPA causes 
p53 mutations and p53 loss of heterozygosity during the malignant stages when 
papillomas progress to squamous and spindle cell carcinoma (Ruggeri et al., 
1991, Burns et al., 1991). 
 
However, there is evidence using DMBA/TPA mouse models suggesting that 
p53-/- mice develop fewer and smaller papillomas compared with p53+/- and 
p53+/+ mice (Kelly-Spratt et al., 2004, Kemp et al., 1993). Additionally, the 
expression of oncogenes such as H-ras on a p53-/- background also failed to 
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accelerate the formation of skin lesions suggesting the epidermis is somehow 
resistant to neoplastic transformation which is often accompanied by p53 loss 
(Greenhalgh et al., 1996). In contrast, mice with cre-mediated keratinocyte-
specific p53 knock-out (p53EKO) were more susceptible to DMBA/TPA-induced 
skin cancer, suggesting that the expression of p53 in epidermal keratinocytes 
promotes tumor suppression (Page et al., 2016). These studies highlight 
discrepancies in determining the role of p53 in tumor suppression during skin 
carcinogenesis and this may be influenced by the level of p53 expression or 
context such as genetic background in mice. Since Mdm2S183A MEFs display 
elevated levels of endogenous p53 when cultured in the presence of oxidative 
stress compared with Mdm2WT MEFs, I explored whether loss of  Mdm2-S183 
phosphorylation will enhance p53-mediated tumor suppression in DMBA/TPA 
treated mice. 
 
Lastly, I also used the K-ras-induced lung cancer model to determine 
whether Mdm2-S183 phosphorylation affects tumorigenesis primarily driven by 
the expression of an oncogene. In MEFs, the expression of p53 and oncogenic 
K-rasG12V triggers cell senescence (Ferbeyre et al., 2002, Serrano et al., 1997, 
Lin et al., 1998). There is evidence to suggest that this senescence is 
independent of p21 expression (Castro et al., 2004), implying that additional 
compensatory signals can modulate the outcome of p53 activation in the 
presence of oncogenic Ras. Additionally, the expression of oncogenic K-ras 
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activates signaling pathways and trigger ROS generation which promotes 
malignant transformation (Park et al., 2014), and ROS-induced premature 
senescence (Kodama et al., 2013, Weyemi et al., 2012). However, endogenous 
K-rasG12D expression does not induce senescence but increases cell proliferation 
in MEFs and developmental defects in mice (Tuveson et al., 2004). This may 
suggest that endogenous Ras expression potentially inhibits the activation of 
downstream effector pathways or the levels were not sufficient to trigger effector 
pathways that mediate senescence.  
 
In contrast, loss of NF1 in human cells, which allows endogenous Ras 
expression, inhibits downstream effector pathways but these cells senesce after 
several passages (Courtois-Cox et al., 2006), thereby ruling out downstream 
effector pathway silencing. Additionally, the notion that endogenous Ras levels 
are not sufficient to trigger senescence was challenged by findings showing that 
preneoplastic pancreatic lesions driven by endogenous levels of oncogenic K-ras 
are positive for various senescence markers, and display activation of 
downstream effectors in pathways governed by Ras expression (Ji et al., 2009). 
These contrasting findings suggest that the type of response from activation of 
endogenous Ras may be context dependent. I hypothesized that Mdm2-S183 
phosphorylation promotes lung tumorigenesis  by lowering p53-mediated 
senescence induced by the expression of endogenous levels of oncogenic K-ras. 
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Results 
 
Diethylnitrosamine-induced liver cancer: Two-week old Mdm2WT and 
Mdm2S183A male mice were injected with DEN and sacrificed after 40 weeks. 
Upon dissecting the mice, 93% of Mdm2WT mice  presented with outwardly visible 
tumors on the liver compared with about 61% of Mdm2S183A mice (Figure 3.1a). In 
addition, Mdm2WT mice had significantly larger and high number of tumors 
compared with Mdm2S183A mice (Figure 3.1b-c). Consistently, the liver weights 
and volumes were significantly higher in Mdm2WT mice than in Mdm2S183A mice. 
Tumors in both Mdm2WT and Mdm2S183A mice also stained positive for glutamine 
synthetase which is one of the markers for liver cancer, suggesting that these 
liver lesions are indeed tumors. Collectively, these data suggest that Mdm2-S183 
phosphorylation increases susceptibility to DEN-induced liver tumorigenesis. 
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Figure 3.1. Phosphorylation of Mdm2-S183 promotes DEN-induced liver 
tumorigenesis. (A) Representative images showing the tumor burden in 
Mdm2
WT
 (n=27) and Mdm2
S183A
 (n=25) mice sacrificed 40 weeks after DEN was 
administered at 2 weeks of age. Percentage of Mdm2
WT
 and Mdm2
S183A
 mice 
with outwardly visible liver nodules at the time of sacrifice (Right panel). (B) Liver 
sections from untreated and DEN-treated Mdm2
WT
 (n=27) and Mdm2
S183A
 (n=25) 
tumor-bearing mice were stained with H&E. scale bar =50um. (C) Body weights, 
liver weights, tumor numbers, and tumor volumes for both Mdm2
WT
 (n=27) and 
Mdm2
S183A 
(n=25) 40 weeks after the administration DEN. Student’s T test 
*p<0.05 and **p<0.01. (D) Higher and lower magnification of glutamine 
synthetase-stained liver sections from 42 week old Mdm2
WT
 and Mdm2
S183A
 
DEN-treated mice (n=3). Scale bar = 100um. 
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The administration of carcinogens such as DEN triggers the generation of 
ROS which can cause DNA adducts through oxidative alteration and strand 
breakage potentially giving rise to cancer causing mutations (Ziech et al., 2010). 
DEN-induced oxidative stress also disrupts antioxidant function in the liver and 
this is thought to contribute to early histopathological alterations observed in DEN 
treated mice (Paula Santos et al., 2014).  I therefore determined whether there 
was a difference in ROS generation between Mdm2WT and Mdm2S183A  livers 
following DEN injection by staining fresh liver cryosections with a redox sensitive 
fluorescent probe dihydroethidium (DHE). The oxidized form of DHE, 2-
hydroxyethidium, intercalates with DNA and displays red fluorescence in the 
nucleus. I found that ROS was generated at comparable levels in Mdm2WT and 
Mdm2S183A  mice  with a time dependent decrease which I observed over the 
course of a week (Figure 3.2a). The fact that there were no differences in the 
amount of ROS in Mdm2WT and Mdm2S183A  livers following DEN injection is in 
line with my findings in MEFs (Figure 2.6). This suggests that Mdm2-S183 
phosphorylation does not alter DEN-induced generation of ROS. 
 
I established that  Mdm2S183A MEFs were more susceptible to p53-
mediated senescence than Mdm2WT MEFs when exposed to oxidative stress 
(Figure 2.4C). Similarly, p53 expression suppresses tumor development and 
progression in hepatic stellate cells by triggering senescence-associated 
secretory phenotype in livers of DEN-treated mice (Lujambio et al., 2013). To 
 
  
63 
examine whether DEN-induced oxidative stress triggers p53 expression and p53-
dependent senescence in mouse livers, I performed western blot analysis using  
protein lysates extracted from livers of DEN-treated mice (Figure 3.2b). The 
protein levels of activated p53 and the senescence marker p16 were increased in 
livers of DEN-treated Mdm2S183A mice relative to Mdm2WT mice. Additionally, p21 
which is often used as marker of p53-mediated senescence was also elevated in 
livers of Mdm2S183A mice compared with Mdm2WT mice. Furthermore, the gene 
expression levels of senescence marker p16 and p53-dependent senescence 
markers p21, and Pai-1 were significantly elevated in Mdm2S183A livers than in 
Mdm2WT livers after DEN administration (Figure 3.2c). These findings suggest 
that loss of Mdm2-S183 phosphorylation promotes p53-mediated senescence in 
the livers of Mdm2S183A  exposed to DEN, potentially contributing to the 
suppression of liver cancer. 
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Figure 3.2. DEN treatment triggers senescence in Mdm2S183A livers treated 
with DEN. (A) Representative images of dihydroethidium staining in liver 
sections from Mdm2
WT
 and Mdm2
S183A
 male mice at various time points post 
DEN administration (n=3). Scale bar is 20m. (B) Western blot analysis of protein 
lysates from liver tissues harvested from DEN-treated Mdm2
WT
 and Mdm2
S183A
 
mice at the indicated time points (n=3). (C) mRNA expression levels for 
senescence genes in livers of young DEN-treated Mdm2WT and Mdm2S183A mice 
(n=3). Data is expressed as mean ± standard deviation. Student’s T test *p<0.05 
and **p<0.01.  
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DMBA/TPA-driven skin tumorigenesis: To investigate whether Mdm2-S183 
phosphorylation affects tumorigenesis in yet another model of carcinogenesis, I 
utilized the two stage DMBA/TPA to induce the initiation and promotion of 
epidermal tumors. DMBA causes mutations in genes such as H-ras in 
keratinocytes and TPA promotes the clonal expansion of mutant cells and loss of 
tumor suppressors such as p53, giving rise to skin tumors (Abel et al., 2009). 
There is evidence showing that p53 expression in the skin epidermis inhibits 
tumor formation  in mouse epidermis (Lyle et al., 2014) (Martinez-Cruz et al., 
2008). Additionally, grafting of keratinocytes deficient for p53 but expressing H-
ras gives rise to malignant transformation which is increased by the loss of one  
allele of p53 (Weinberg et al., 1994). These studies together with the one using 
conditional deletion of p53 in keratinocytes mentioned in the introduction of this 
chapter, underscores the  role of p53 in suppressing DMBA/TPA-induced       
skin tumorigenesis.  
 
However, there is contrasting evidence using DMBA/TPA models showing 
that  the expression of p53 and H-ras promote papilloma formation but reduces 
malignant progression (Kemp et al., 1993). Additionally, expression of Ras 
oncogenes activate p19Arf which inhibits Mdm2 thereby activating p53-dependent 
growth arrest (Kelly-Spratt et al., 2004). Furthermore, in p19Arf deficient mice 
subjected to the DMBA/TPA protocol, the rate of papilloma growth was higher 
than in wild type  and p53-/- mice. This further suggests that p53 dependent and 
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independent functions regulate tumor suppression in the epidermis. Additionally, 
various ways of activating p53 in the epidermis may have different effects on 
tumor suppression. 
 
Since MEFs expressing Mdm2 that cannot be phosphorylated at S183 
exhibited elevated levels of p53 compared with wild type MEFs in the presence 
of oxidative stress, I hypothesized that Mdm2S183A mice will be less susceptible to 
epidermal tumorigenesis induced by DMBA/TPA. I postulated that when 
Mdm2S183A mice are exposed to oxidative stress and oncogene activation caused 
by the topical application of DMBA/TPA, the levels of p53 activation and function 
will exceed those observed in Mdm2WT. As a result, this would activate 
downstream p53 effector pathways that mediate tumor suppression, such as the 
p53-dependent senescence observed in Mdm2S183A MEFs.  
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Figure 3.3. Mdm2-S183 phosphorylation promotes skin tumorigenesis.     
(A) Schematic illustration of DMBA/TPA application timing of skin carcinogenesis 
protocol. (B) Percentage of Mdm2
WT
 (n=23) and Mdm2
S183A
 (n=22) mice with 
papillomas. (C) Representative photographs of Mdm2
WT 
(n=3) and Mdm2S183A 
(n=3) mice with papillomas after 32 weeks of TPA promotion. (D) Representative 
H&E images of papillomas isolated from Mdm2
WT 
and Mdm2S183A mice after 32 
weeks of TPA treatment. Scale bar = 500um. (E) Papilloma volume per mouse in 
Mdm2WT (n=23) and Mdm2S183A (n=22) mice. Data is expressed as mean ± 
standard deviation. (F) Number of papillomas per mouse in Mdm2WT (n=22)and 
Mdm2S183A (n-23) mice. Data is expressed as mean ± standard deviation. Two 
way Anova and paired Student T tests  **p<0.01. 
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Tumor initiation in Mdm2WT and Mdm2S183A mice was achieved by the 
topical application of DMBA  in two-month old mice. Two weeks post DMBA 
administration, I began twice-weekly applications of TPA to promote tumor 
formation for up to 35 weeks (Figure 3.3a). Mdm2S183A mice were significantly 
less susceptible to papilloma development, with the first tumors in Mdm2S183A 
mice appearing 2 months after the first papillomas appeared in Mdm2WT mice 
(Figure 3.3b). About 86.9% of Mdm2WT mice developed at least one or more 
papillomas compared to 40.9% of Mdm2S183A mice (Figure 3.3b). Furthermore, 
Mdm2S183A mice also exhibited significantly smaller tumors compared to Mdm2WT 
mice as shown the papilloma images, histological staining, and papilloma 
volumes (Figure 3.3c-e). Moreover, Mdm2WT mice had significantly higher 
number of tumors compared with Mdm2S183A mice (Figure 3.3f). Taken together,  
these findings indicate that Mdm2-S183 phosphorylation enhances epidermal 
tumor formation in mice exposed to topical carcinogens. 
 
Next, I performed western blots using protein lysates extracted from the 
skin of mice in the first few weeks of TPA promotion before Mdm2WT starts 
presenting with papillomas to determine the expression of senescence markers 
(Figure 3.4a). In Mdm2WT mice, DMBA treatment led to a minor induction of p53 
expression and no p21 protein expression (Figure 3.4a). In contrast, DMBA 
treatment induced the expression of both p53 and p21 proteins in Mdm2S183A 
mice with very minimal expression of activated phospho-p53 (Figure 3.4a). 
 
  
69 
However, there were no differences in the levels of p53 and phospho-p53 protein 
expression between Mdm2WT and Mdm2S183A mice during the TPA promotion 
period. Nonetheless, p21 and p16 protein levels were elevated in Mdm2S183A 
mice compared with Mdm2WT mice, with some of the Mdm2WT mice losing both 
p21 and p16 expression around 6 weeks, that is two weeks before the 
emergence of papillomas (Figure 3.4a and b). This demonstrates that Mdm2-
S183 phosphorylation inhibits p53 activation during the initiation stages with 
DMBA and reduces p53-dependent senescence during TPA promotion. 
 
Furthermore, I stained for SA- galactosidase in Mdm2WT and Mdm2S183A 
mice skin to determine whether there was any evidence of senescence during 
TPA promotion. Indeed, there was positive staining for SA- galactosidase in the 
skin of both Mdm2WT and Mdm2S183A mice, with prolonged SA- galactosidase 
staining in Mdm2S183 (Figure 3.4b). These findings point to a role of p53-mediated 
senescence in contributing to tumor suppression in Mdm2S183A skin treated with 
DMBA/TPA. In sum , the data suggests the phosphorylation of Mdm2-S183 
promotes epidermal tumorigenesis partly by diminishing p53-mediated 
senescence triggered by topical application of carcinogens in mice.  
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Figure 3.4. Mdm2-S183 phosphorylation promotes epidermal 
tumorigenesis. (A) Western analysis of protein extracts from Mdm2
WT 
and 
Mdm2S183A mice skin treated with TPA for the indicated time in weeks (n=3). (B) 
Senescence-associated-β-galactosidase staining in skin of Mdm2
WT 
and 
Mdm2S183A mice treated with TPA for the indicated time in weeks. Senescence-
associated-β-galactosidase stained sections were counterstained with nuclear 
fast red (n=3). Scale bar =20 µm.  
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Oncogenic K-ras driven lung cancer: The expression of p53 together with 
oncogenic Ras triggers senescence in vitro (Serrano et al., 1997, Ferbeyre et al., 
2002). Senescence induced by the expression of oncogenic Ras is thought to 
impede cellular transformation.  However, there are discrepancies regarding the 
role of endogenous levels of oncogenic Ras in inducing senescence.  MEFs 
derived from K-rasG12D mice in which Ras is expressed at endogenous levels 
displayed enhanced proliferation and susceptibility to transformation (Tuveson et 
al., 2004). Additionally, expression of  activated B-Raf (B-rafV600E) which is 
downstream of Ras, failed to trigger senescence in vitro (Pritchard et al., 1995). 
In contrast to these findings, in vivo expression of oncogenic K-RasGV12 and B-
rafV600E triggers senescence in premalignant adeno carcinoma (Collado et al., 
2005, Dankort et al., 2007).  Additionally, endogenous levels of K-rasGV12 induced 
senescence in PanIN lesions (Ji et al., 2009). In the aforementioned in vivo 
studies, tumors progressed to malignant cancer upon the loss of p53, 
underscoring the role of p53-mediated senescence in suppressing tumor 
progression driven by the expression of endogenous oncogenic Ras. 
 
Additionally, it is well established that oncogenic Ras expression triggers the 
generation of reactive oxygen species (Lee et al., 1999, Colavitti and Finkel, 
2005). Therefore, I postulated that blocking Mdm2-S183 phosphorylation, which 
led to increased p53-mediated senescence in the presence of oxidative stress in 
MEFs, suppresses lung tumorigenesis driven by the expression of endogenous 
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oncogenic Ras. First, I transduced Mdm2WT, Mdm2S183A, and p53-/- MEFs with an 
empty retroviral vector (Vector) or its derivative expressing oncogenic Ras (K-
rasG12V) and stained cells with DCFDA to determine the levels of ROS. There 
were no significant differences in the level of ROS among Mdm2WT, Mdm2S183A, 
and p53-/- MEFs when transduced with vector (Figure 3.6a). Similarly,  there were 
also no significance differences in the level of ROS among Mdm2WT, Mdm2S183A, 
and p53-/- MEFs when transduced with K-rasG12V (Figure 3.5a). However, ROS 
levels were significantly elevated in Mdm2WT, Mdm2S183A, and p53-/- MEFs 
transduced with oncogenic K-ras than in Mdm2WT, Mdm2S183A, and p53-/- MEFs 
transduced with an empty vector, suggesting that expression of oncogenic Ras 
promotes  ROS accumulation.  
 
Secondly, I stained vector- and K-rasG12V-transduced MEFs  for senescence 
associated -galactosidase  to measure senescence. The percentage of cells 
that stained positive for SA- galactosidase was significantly increased in 
Mdm2S183A MEFs expressing K-rasG12V compared with their Mdm2WT counterparts  
and no effect was observed in p53-/- MEFs (Figure 3.5b). In addition, I extracted 
protein lysates from Mdm2WT and Mdm2S183A MEFS transduced with either vector 
and K-rasG12V  and performed  western blot analysis. K-rasG12V triggered the 
expression of p53 and phospho-p53 at comparable levels in Mdm2WT and 
Mdm2S183A MEFs. However, Mdm2S183A MEFs had higher protein levels of 
senescence markers p21 and p16 than Mdm2WT MEFs (Figure 3.5c). This 
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indicates that  Mdm2-S183 phosphorylation reduces the amount of p53-mediated 
senescence induced by endogenous levels of oncogenic K-ras. 
 
Next, I examined the effects of Mdm2-S183 phosphorylation on lung cancer 
induced by the expression of oncogenic  K-ras. To this end, 8-12 week old K-
rasG12D;Mdm2WT and K-rasG12D;Mdm2S183A mice were infected with aerosolized 
adenoviral CMV-Cre and were sacrificed after 7.5 months. K-rasG12D;Mdm2WT 
and K-rasG12D;Mdm2S183A mice both presented with lung tumors (Figure 3.5d). I 
found that tumor volumes in K-rasG12D;Mdm2S183A mice were significantly lower 
than in K-rasG12D;Mdm2WT mice (Figure 3.5d). These findings indicate that Mdm2-
S183 phosphorylation promotes Ras-induced lung tumorigenesis, potentially by 
altering p53-dependent senescence. 
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Figure 3.5. Mdm2-S183 phosphorylation enhances the development of K-
ras-driven tumors. (A)Flow cytometry analyses (left) and quantification of DCF 
staining (right) in Mdm2
WT
, Mdm2
S183A
, and p53
-/-
 MEFs cultured at 5% oxygen in 
media supplemented with NAC and transduced with pBabe (vector) or its 
derivative expressing oncogenic Ras (G12V). Data is expressed as mean 
fluorescence ± standard deviation. Student’s T test **p<0.01 (n=3). (B) 
Representative images showing results for senescence-associated β-
galactosidase staining (left) and quantification of positively stained Mdm2
WT 
and 
Mdm2
S183A 
mouse embryonic fibroblasts (right) cultured at 5% oxygen and 
transduced with pBabe (vector) or its derivative expressing 
oncogenic Kras(G12V). Data is expressed as mean ± SD. Student’s T test 
*p<0.05 and **p<0.01 (n=3). (C) Western blot analyses of Mdm2
WT
 and 
Mdm2
S183A
 mouse embryonic fibroblasts transduced with pBabe (vector) or its 
derivative expressing oncogenic Ras (G12V) (top). Quantification of bands on 
western blot relative to the loading control protein, vinculin (bottom) (n=3). (D) 
Representative images of H&E stained lungs from Kras
+/G12D
;Mdm2
WT
 (n=14) 
mice and Kras
+/G12D
;Mdm2
S183A
 (n=16) mice 250 days after the administration of 
Ad-CMV-cre (top). Quantification of area occupied by the tumors in 
Kras
+/G12D
;Mdm2
WT
 and Kras
+/G12D
;Mdm2
S183A
 mice (bottom). Data is expressed 
as mean ± SD. Student’s T test **p<0.01. 
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Brief recap of findings from Mdm2 phosphorylation mutant mice 
 
It is beginning to emerge that post translational modifications of Mdm2 
play pivotal roles in regulating p53 functions in response to stress. Modifications 
on various Mdm2 residues seem to influence distinct downstream p53 functions, 
suggesting the existence of a layered and fine-tuned regulation of Mdm2-p53 
signaling. In our lab we have focused on investigating the role played by Mdm2 
phosphorylation in regulating p53-dependent stress responses. We have 
developed several knock-in mouse models which express Mdm2 that cannot be 
phosphorylated by c-Abl (Mdm2Y393F mice),  ATM (Mdm2S394A mice), or both 
kinases ( double mutant Mdm2Y393F;S394A mice) and S394 phosphomimic 
(Mdm2S394D) mice. Previous studies using the aforementioned models paved way 
for the work presented in this dissertation.  
 
Briefly, Mdm2-S394 phosphorylation by ATM promotes p53 stability and 
activation following DNA damage (Gannon et al., 2012b). As such, loss of Mdm2-
S394 phosphorylation, modelled in Mdm2S394A mice, leads to diminished p53 
activation and stability, and radioresistance in mice. These findings demonstrate 
that phosphorylation of Mdm2-S394 influences p53-mediated DNA damage 
responses in vivo. Mdm2S393A mice are more prone to spontaneous 
tumorigenesis compared with Mdm2WT and Mdm2S394D. Furthermore, Mdm2S394A 
mice display accelerated lymphomagenesis driven by the expression of Eμ-myc 
(Carr et al., 2016a). In contrast, these mice have decreased lymphomagenesis 
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resulting from exposure to ionizing radiation. These findings imply contrasting 
effects of Mdm2-S394 phosphorylation by ATM on tumor suppression. 
 
On the other hand, Mdm2-Y393 phosphorylation by c-Abl does not alter 
p53 stability, activation, and p53-dependent apoptosis following DNA damage. 
However, Mdm2Y393F show increased bone marrow repopulation, recover from 
radiation exposure more rapidly, and are therefore radioresistant (Carr et al., 
2016b). Additionally, Mdm2Y393F mice are more susceptible to spontaneous and 
Eμ-myc driven tumorigenesis, suggesting that Mdm2-Y393 phosphorylation 
alters tumor suppression in ways that cannot be extrapolated from p53 
expression and activity following DNA damage in Mdm2Y393F mice. Furthermore, 
Mdm2Y393F/S394A mice display phenotypes resembling those of Mdm2S394A mice, 
suggesting no additive effects of these two phosphorylation events. Based on 
these aforementioned studies, it is becoming clear that Mdm2 phosphorylation 
differentially alters p53 responses following exposure to stress. This is critical in 
therapeutic development, since this provides alternative avenues to obtain 
multiple desirable responses. 
 
In vitro transfection-based studies demonstrated that Mdm2 
phosphorylation by Akt at S163 and S183 enhances Mdm2 nuclear localization 
thereby increasing Mdm2-mediated degradation of p53 (Mayo and Donner, 2001, 
Zhou et al., 2001). In this dissertation, I presented data from my studies 
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investigating the functional relevance of Mdm2 phosphorylation at S163 and 
S183 by Akt at endogenous levels. I mainly focused on determining how Mdm2-
S183 phosphorylation affects processes subject to control by p53-dependent 
pathways such as development, cell proliferation, DNA damage response, 
tumorigenesis, and glucose metabolism. 
 
Mdm2-S183 phosphorylation in development 
 
Mdm2S163A and Mdm2S183A mice were viable, fertile, and were obtained at 
Mendelian ratios (Figure 2.1), suggesting that Mdm2 phosphorylation by Akt is 
dispensable for development. This is in contrast to what is observed in Mdm2-/- 
mice that are embryonic lethal and are rescued by the concomitant loss of p53 
(Jones et al., 1995, Montes de Oca Luna et al., 1995). Embryonic lethality in 
Mdm2-/- embryos is attributed to elevated p53-dependent apoptosis (Chavez-
Reyes et al., 2003). In vitro, Mdm2 phosphorylation at either S163 or S183 
reduces p53 levels and activity (Mayo and Donner, 2001, Zhou et al., 2001). 
Therefore, I proposed that Mdm2S183A and Mdm2S163A mice may exhibit 
embryonic lethality due to increased p53 activity. Alternatively, if they are not 
embryonic lethal, I postulated that Mdm2S183A and Mdm2S163A mice may show 
signs of premature aging.  However, culturing Mdm2WT and Mdm2S183A MEFs at 
low oxygen with NAC (Figure 2.3), conditions which probably closely resemble 
those present in utero, exerts minimal effects on p53 expression, activation and 
cell proliferation. Therefore, it is plausible that loss of Akt-mediated 
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phosphorylation of Mdm2 in Mdm2S163A and Mdm2S183A embryos does not 
increase p53 levels and activity, contrary to what is observed in Mdm2-/- 
embryos, hence the absence of an embryonic lethal phenotype. 
 
There is evidence showing that elevated levels of p53 promote premature 
aging in mice (Tyner et al., 2002). The conditional expression of non-functional 
Mdm2 lacking exons 11-12 (Mdm2 Δ11-12) in the skin epidermis using K5-cre 
leads to pre-mature aging phenotypes, elevated p53 activity and senescence in 
the skin (Gannon et al., 2011). I postulated that loss of Mdm2-S163 or Mdm2-
S183 phosphorylation promotes premature aging phenotypes due to increased 
p53 activity. However, there were no significant differences in body weights 
(Figure 2.1g), longevity (Figure 2.1h), and physical appearance between controls 
and Mdm2 mutant mice. The fact that unchallenged Mdm2WT and Mdm2S183A 
mice are phenotypically indistinguishable suggests that loss of Akt-mediated 
phosphorylation of Mdm2 does not promote premature aging in mice. These 
findings are consistent with my findings in MEFs showing that at low oxygen, 
Mdm2WT and Mdm2S183A MEFs express slightly different levels of p53, but this 
difference was small enough to not affect cell proliferation and has minimal 
effects on p53-mediated senescence (Figure 2.2 and 2.5). As mentioned before, 
these low oxygen cell culture conditions potentially closely mimic what happening 
in vivo, and this may account for the similar phenotypes between unchallenged 
Mdm2WT and Mdm2S183A mice.  
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Mdm2S183A MEFs proliferated at low oxygen but failed to do so at high 
oxygen implying that Mdm2-S183 phosphorylation sensitizes cells to oxidative 
stress present in conventional cell culture incubators not adjusted for oxygen 
levels (Figure 2.3). Mdm2S183A mice displayed significantly elevated levels of p53  
at high oxygen compared to low oxygen, suggesting that Mdm2-S183 
phosphorylation lowers p53 levels in the presence of oxidative stress. As a future 
direction, it is important to examine the effects of Mdm2 phosphorylation on 
development and maybe aging in Mdm2WT and Mdm2S183A mice treated with 
paraquat, a widely used herbicide and ROS inducer in mice (Castello et al., 
2007). This may include the administration of paraquat in pregnant Mdm2WT and 
Mdm2S183A mice to study resulting developmental phenotypes. In addition, the 
administration of paraquat starting at a young age in Mdm2WT and Mdm2S183A  
mice would probably activate p53 expression more in Mdm2S183A mice than with 
Mdm2WT mice, and this may cause premature aging. Additionally, simple culture 
of Mdm2WT and Mdm2S183A  embryos in vitro at the different oxygen tensions, 
could shed some light on the role of Akt-Mdm2 signaling in development. 
Furthermore, generation of double mutant mice (Mdm2S163A;S183A) may provide 
more information of the role of Mdm2 phosphorylation by Akt in development. It is 
conceivable that in Mdm2S183A  mice, phosphorylation of S163 compensates for 
the loss of S183 phosphorylation and vice versa. 
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Mdm2-S183 phosphorylation in cell proliferation  
 
At endogenous levels, the phosphorylation of Mdm2-S183, but not Mdm2-
S163, is required for normal cell proliferation in MEFs (Figure 2.2 and 2.3). 
Additionally, Mdm2S183A MEFs were more prone to premature senescence 
compared with Mdm2WT and Mdm2S163A MEFs, hence they failed to proliferate 
(Figure 2.2). Moreover, Mdm2-S183 residue is also more conserved than S163 
(Lane et al., 2011). Interestingly, the proliferation defect in Mdm2S183A MEFs was 
rescued by culturing these cells at low oxygen in the presence of reactive oxygen 
species scavenger, N-acetyl cysteine (NAC) (Figure 2.3). This suggests that 
Mdm2-S183, but not Mdm2-S163, phosphorylation protects cells from premature 
senescence induced by oxidative stress. It will be useful to also cross Mdm2S183A 
mice with p53-/- mice to further determine that senescence observed in 
Mdm2S183A is indeed p53-dependent. These proliferation assay results are in 
contrast to findings using Mdm2Y393F and Mdm2S394A MEFs which exhibited 
normal proliferation kinetics similar to Mdm2WT MEFs (Gannon et al., 2012a, Carr 
et al., 2016c). This further reinforces the notion that different Mdm2 
phosphorylation events have contrasting functions. 
 
Mdm2S183A MEFs cultured at high oxygen expressed elevated levels of 
p53 which were accompanied by reduced Mdm2 protein levels compared with 
Mdm2WT MEFs (Figure 2.5). Additionally, activation of Akt using IGF-1 led to 
increased p53 expression in Mdm2S183A than in Mdm2WT MEFs. This increase in 
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p53 levels in Mdm2WT was accompanied by a decrease in Mdm2 levels. This 
data suggests that phosphorylation of Mdm2-S183 stabilizes Mdm2 in the 
presence of oxidative stress and promotes p53 degradation. However, Mdm2 
phosphorylation following stress like DNA damage generally destabilizes Mdm2 
(Gannon et al., 2012a, Meek and Hupp, 2010, Carr et al., 2016a), potentially 
through ubiquitin-mediated degradation. For instance,  ATM phosphorylates and 
promotes nuclear localization of casein kinase I (CKI) (Wang et al., 2012). 
Phosphorylation of Mdm2 by CKI at multiple serine residues in response to DNA 
damage facilitates its interaction with SCF (beta-TRCP) which ubiquitinates 
Mdm2 and promotes its degradation (Inuzuka et al., 2010).  This suggests that 
phosphorylated Mdm2 is a target for E3 ligases following exposure to stress.  
 
Since Mdm2-S183  phosphorylation enhances Mdm2 localization into the 
nucleus (Figure 2.8), it is plausible that this protects some of the Mdm2 from E3 
ligases, hence the increased stability observed in Mdm2WT MEFs than in 
Mdm2S183A MEFs. Reduced Mdm2 stabilization in Mdm2S183A MEFs may also be 
due to altered levels of other post translational modifications that promote Mdm2 
stabilization such as sumolyation (Buschmann et al., 2001), or decreased 
expression of Mdm2 deubiquitinating enzymes such as HAUSP (Meulmeester et 
al., 2005). Therefore, the mechanism governing how Mdm2-S183 
phosphorylation alters Mdm2 protein levels still need to be elucidated. This may 
include determining the levels of Mdm2 ubiquitination in Mdm2WT and Mdm2S183A 
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MEFs. In addition, looking at the presence or expression levels of other proteins 
or modifications that can enhance Mdm2 degradation may shed some light on 
the effects of Mdm2-S183 phosphorylation on Mdm2 stability. Furthermore, 
pulse-chase experiments on nuclear and cytoplasmic lysates from high oxygen 
Mdm2WT and Mdm2S183A MEFs can also reveal how Mdm2 phosphorylation by 
Akt alters Mdm2 stability. 
 
My findings showing that Mdm2-S183 phosphorylation promotes cell 
proliferation in MEFs in the presence of oxidative stress (Figures 2.2 and 2.3), 
are consistent with the well-established role of Akt in promoting cell growth, 
survival, and proliferation. Findings from over expression studies in vitro showed 
that Mdm2 phosphorylation by Akt reduces p53 levels and activity, and this is 
thought to be one of the ways through which Akt promotes cell survival.  PI3K/Akt 
signaling promotes oxidative metabolism in the mitochondria critical for 
promoting cell survival and this contributes to the generation of ROS (Schieber 
and Chandel, 2014). ROS can activate the PI3K/Akt pathway (Ushio-Fukai et al., 
1999, Okoh et al., 2013), suggesting the existence of a cyclical relationship 
between ROS and the PI3K/Akt pathway. High levels of ROS can activate p53’s 
prooxidant functions resulting in senescence and/or apoptosis (Liu et al., 
2008).Therefore, it is conceivable that ROS promotes Mdm2-S183 
phosphorylation by Akt and the subsequent reduction in p53 activity contribute to 
cell proliferation and survival under oxidative stress. To further understand the 
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effects oxidative stress on Akt/Mdm2/p53 signaling axis, I still have to ascertain 
the activation of Akt by ROS in Mdm2WT and Mdm2S183A MEFs cultured at high 
oxygen compared to those at low oxygen or low oxygen treated with hydrogen 
peroxide.  
 
Moreover, there is also a possibility that other kinases similar to Akt may 
phosphorylate these residues. For instance, serum and glucocorticoid regulated 
kinase 1 (Sgk1) has been shown to phosphorylate human Mdm2-S166 and -
S188 (Amato et al., 2009). IGF-1 experiments in Chapter II show that Akt can 
potentially phosphorylate Mdm2 and affect p53 levels. Therefore, it is possible 
that Sgk1 also phosphorylates these residues and affect p53 levels and function. 
Experiments to determine these kinases may include pull-down of wild type and 
single or double mutant Mdm2 and perform western blot analyses with currently 
non-existent antibodies against Mdm2 phospho-S163 and phospho-S183. 
Additionally, in vitro kinase assays with either wild type and single or double 
mutant Mdm2 with various kinases that have phosphorylation motifs present in 
Mdm2 can further shed some light on the type of kinases that modifies the 
residues in question. 
 
Another alternative will be to perform a screen to determine the 
phosphatase responsible for dephosphorylating these serine residues. For 
instance, overexpression of specific phosphatases may cause phenotypes 
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similar to those observed in Mdm2S163A and Mdm2S183A MEFs. It is possible that 
different phosphatases influence the phosphorylation status of these two 
residues hence the different phenotypes observed. Alternatively, Mdm2-S183 
may be preferentially phosphorylated compared with Mdm2-S163 and pull-down 
and mass spectrometry analyses may determine the phosphorylation status 
regarding the context and levels. Also, generating Mdm2 phosphomimic mice 
models in which either Mdm2-S163 and/or Mdm2-S183 are substituted with 
aspartic acid will allow me to further demonstrate that the effects observed in 
Mdm2 mutant MEFs used in my studies are due to phosphorylation. Additionally, 
if Mdm2S183D MEFs phenotypically resemble Mdm2WT MEFs, this will further 
demonstrate that the observed proliferation defects and the effects on p53 levels 
and function are due to the mutation in Mdm2. 
 
 
Mdm2-S183 phosphorylation in DNA damage responses 
 
Emerging evidence shows that Mdm2 phosphorylation is critical in 
regulating the DNA damage response. Mdm2-S394 phosphorylation by ATM  
promotes p53 stabilization and activity in response to DNA damage (Gannon et 
al., 2012a). However, Mdm2-Y393 phosphorylation does not affect p53 
stabilization and activity following DNA damage, but promotes bone marrow 
repopulation thereby causing radioresistance in mice (Carr et al., 2016c). 
Similarly, there was no significant difference in p53 stabilization and activation, 
p53-dependent apoptosis, and cell cycle arrest between Mdm2WT and Mdm2S183A 
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MEFs in response to DNA damage (Figure 2.9-2.10). This indicates that Mdm2-
S183 phosphorylation does not affect p53-mediated responses to DNA damage 
from ionizing radiation, etoposide, and doxorubicin examined here. It is plausible 
that Akt-mediated phosphorylation of Mdm2-S163 following DNA damage 
compensates for loss of  Mdm2-S183 phosphorylation. This may explain the 
comparable levels of p53 activation and stability, and cell cycle progression in 
Mdm2S183A MEFs compared with controls.  However, Mdm2S183A MEFs exhibited 
more 8-Oxo-2'-deoxyguanosine adducts than Mdm2WT MEFs, suggesting that 
Mdm2S183A MEFs are more prone to oxidative DNA damage (Figure 2.6). It 
seems the effects of Mdm2-S183 phosphorylation in DNA damage response are 
dependent on the type of stress signals causing the damage. In addition, it is 
also possible that the time cells are exposed to the stress causing the DNA 
damage affects the type of response. Time spent under exposure to genotoxic 
agents in low oxygen MEFs used to study the DNA damage response is different 
from the chronic exposure to oxidative stress experienced by high oxygen MEFs. 
Furthermore, ionizing radiation and the genotoxic drugs examined here induce 
double stranded breaks whilst oxidative stress often induce DNA base oxidation 
and alkylation.  
 
It will also be informative to generate and use the double mutant 
Mdm2S163/S183A mice to further characterize the effects of Mdm2 phosphorylation 
in the DNA damage response. The proposed model will eliminate the 
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confounding effects of Mdm2-S163 phosphorylation in potentially influencing the 
observed results in Mdm2S183A MEFs and mice following DNA damage. 
Additionally, if reagents were available, it will be important to confirm Mdm2 
phosphorylation following DNA damage and exposure to oxidative stress. 
 
Mdm2-S183 phosphorylation in tumorigenesis 
 
Here, I have shown that Mdm2S183A mice were less susceptible to DEN-
induced tumorigenesis compared with Mdm2WT mice (Figure 3.1). In addition, 
there was no difference in the amount of DEN-induced ROS between DEN 
Mdm2S183A mice and Mdm2WT mice (Figure 3.2). Since Mdm2S183A livers 
expressed significantly higher levels of p53-dependent senescence markers 
compared with controls, I concluded that Mdm2-S183 phosphorylation promotes 
DEN-induced hepatocellular carcinoma (HCC) by inhibiting p53-dependent 
senescence triggered by ROS and DEN-induced DNA damage.  
 
A recent study showed that CD44 expression induced by DEN 
administration enhances Akt-mediated phosphorylation of Mdm2 leading to 
reduced p53-dependent senescence and apoptosis in response to DEN-induced 
DNA damage (Dhar et al., 2018). This promotes the proliferation of damaged 
cells that will act as HCC progenitors. These findings are consistent with the data 
presented here showing that Mdm2-S183 phosphorylation by Akt diminishes 
p53-dependent senescence and promotes liver tumorigenesis (Figure 3.1 and 
3.2). In Mdm2S183A mice treated with DEN, it is plausible that the observed p53-
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mediated senescence, facilitates the clearance of potential HCC progenitors 
together with reduced proliferation and increased cell death. However, since I did 
not observe differences in DNA damage induced by DEN in Mdm2S183A and 
Mdm2WT mice, it will be informative to examine the effects of Akt-mediated 
phosphorylation of Mdm2 on DEN-induced compensatory proliferation and cell 
death.  
 
Moreover, It is also possible that both Mdm2-S163 and -S183 
phosphorylation promote DEN-induced liver tumorigenesis but through slightly 
different mechanisms. Hence, it is important to determine the effects of Mdm2-
S163 phosphorylation in DEN-mediated liver tumorigenesis in Mdm2S163A mice. 
Additionally, determining whether the suppression of DEN-induced liver cancer in 
double mutant mice (Mdm2S163A/S183A) is comparable to those of CD44-/- mice will 
also shed some light on the individual contribution of each phosphorylation site in 
promoting liver tumorigenesis. 
 
Mdm2-S183 phosphorylation also promotes skin neoplasia following 
exposure to carcinogens DMBA and TPA (Figure 3.3-3.4). Overall, Mdm2S183A 
mice exhibited reduced  papilloma incidence, volume, and number compared 
with Mdm2WT mice. Similar to DEN-liver cancer model, there was evidence of 
p53-dependent senescence which likely contributes to tumor suppression in 
Mdm2S183A mice. Administration of TPA is known to cause oxidative stress 
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(Perchellet and Perchellet, 1989, Perchellet et al., 1988). Therefore, it is 
conceivable that in Mdm2S183A MEFs, elevated levels of ROS from the 
administration of TPA triggered p53 activation and the expression of senescence 
regulators like p21. Notably, some mice lost these senescence markers a few 
weeks before the presentation of papillomas, suggesting that loss of senescence 
potentially facilitates the progression from epidermal hyperplasia to papilloma 
formation. Additionally, unlike Mdm2S183A mice, there was barely any positive 
staining for senescence in skin of Mdm2WT mice after a month on TPA promotion, 
further implying that p53-mediated senescence contributes to tumor suppression. 
It is also important to note that p53 protein expression was maintained even to 
the point when Mdm2WT mice started presenting with papillomas. This may 
suggest the presence of additional pro-tumorigenic mutations or activation of 
other pathways that may affect downstream p53 signaling. 
 
Susceptibility to DMBA/TPA-induced tumorigenesis depends on the 
genetic background in mice (Boutwell, 1964). This stems mainly from differences 
in metabolizing the tumor promoting agents as well as their mode of action in 
promoting tumorigenesis (Slaga, 1983). More sensitive models develop 
papillomas sooner and progress to squamous cell carcinomas in about 20 
weeks, which may not occur in C57BL/6 mice since they are the least sensitive 
(DiGiovanni et al., 1993, DiGiovanni et al., 1991). Since p53 is lost during these 
malignant stages, backcrossing the Mdm2 mutation to another strain more 
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sensitive to DMBA/TPA tumorigenesis will be more effective at delineating the 
role of Mdm2 phosphorylation by Akt on p53-mediated tumor suppression. 
PI3K/Akt pathway is also activated by the administration of DMBA and TPA 
(Suzuki et al., 2003). It is plausible that Mdm2-S183 phosphorylation, which 
increases Mdm2 nuclear localization and stability, may also hasten the loss of 
p53 to promote malignant tumor growth. Moreover, DMBA/TPA-induced tumors 
are primarily papillomas and there is no human equivalency.  Therefore, sensitive 
strains that progress to spindle and squamous cell carcinoma which is equivalent 
to human squamous cell carcinoma will provide more therapeutically relevant 
information regarding the role of Akt-signaling to Mdm2 in epithelial cancers. 
   
Oncogenic K-ras activate many pathways including the PI3K/Akt pathway 
to promote cell growth, proliferation, and survival. Oncogenic K-ras cooperates 
with p53 to induce senescence (Serrano et al., 1997) (Ferbeyre et al., 2002). 
Senescence is often observed during the early stages of K-ras driven 
tumorigenesis and contributes to tumor suppression (Pylayeva-Gupta et al., 
2011). I found that oncogenic Ras expression triggered the accumulation of ROS 
(Figure 3.5a), and Mdm2S183A MEFs were more prone to p53-mediated 
senescence triggered by oncogenic Ras expression (Figure 3.5b-c). 
Furthermore, phosphorylation of Mdm2 at S183 increased susceptibility to 
oncogenic K-ras-driven lung tumorigenesis in mice (Figure 3.5d). These findings 
suggest that oncogenic-ras expression triggers ROS accumulation and elevates 
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p53 expression giving rise to senescence which likely contributed to enhanced 
tumor suppression observed in K-rasG12D/+, Mdm2S183A mice. 
 
Oncogenic mutations in various isoforms of Ras also have distinct 
functional consequences in cancer (Haigis et al., 2008). There is evidence 
showing that mutations at the three hot spots in K-ras confer different oncogenic 
potencies, suggesting that G12 mutations may have dissimilar effects compared 
with G13 and Q61 mutations (Hunter et al., 2015, Ihle et al., 2012). Therefore, 
the effect of Mdm2-S183 phosphorylation in tumor suppression may be 
differentially altered depending on the type of K-ras mutation or the isoform of 
oncogenic Ras being expressed. Since Mdm2S183A MEFs expressing K-rasG12V 
exhibited more senescent cells compared with Mdm2WT MEFs, future work may 
focus on determining the presence and amount of senescence during the early 
stages of lung cancer in K-rasG12D/+;Mdm2WT and K-rasG12D/+;Mdm2S183A mice. 
This will provide information on whether the effects of Mdm2-S183 
phosphorylation on tumorigenesis are similar in cells expressing either the G12V 
or G12D mutations. Nonetheless, findings from the DMBA/TPA model in which 
H-ras (Brown et al., 1990) and K-ras mutations (Huang and Balmain, 2014) play 
pivotal roles in tumor initiation, were consistent with my findings using the K-ras 
lung cancer model. This implies that the effects of Mdm2-S183 phosphorylation 
may be similar in cancer models expressing different isoforms of Ras.  
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In most carcinogen-induced cancer models, including the ones examined 
here, the immune cells play a pivotal role in facilitation tumor formation through 
inflammation. Therefore, it will be important to generate tissue specific 
Mdm2S183A transgenic mice in which these immune cells express wild type Mdm2 
since the effects of Mdm2-S183A mutation on other critical cells involved in 
tumor formation is unknown. In addition, tissue specific expression may be more 
physiologically relevant since most cancer causing mutations are somatic and 
not germline. Therefore, despite the Mdm2S183A mutation not being cancer 
causing in my studies, it will be more informative to understand its effects in a 
tissue specific context in which other cells, such as immune cells, express wild 
type Mdm2.  
 
Mdm2-S183 phosphorylation may exert different effects in suppressing 
tumorigenesis induced by other oncogenes such as Myc and Beta-catenin. There 
is evidence suggesting that expression of Myc promotes the accumulation of 
ROS and reduces p53-mediated DNA damage responses (Vafa et al., 2002). 
Expression of oncogenes, such as Myc, can trigger the loss of p53 or the 
negative regulator of Mdm2 known as Arf (Zindy et al, 1998). Therefore, it is 
possible that in tumor models driven by the expression of Myc, Mdm2S183A mice 
will exhibit enhanced tumor suppression through senescence facilitated by Myc-
induced increase in ROS accumulation and Mdm2-S183A protein expression. 
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There is evidence demonstrating that oxidative stress can activate Wnt 
and Beta-catenin signaling (Funato et al., 2006). In contrast, other studies have 
shown that oxidative stress inhibits the downstream effects of Wnt and Beta-
catenin signaling by increasing the activity of FOXO transcription factors to 
reduce cell proliferation allowing for oxidative DNA damage repair (Essers et al., 
2005). The discrepancy in these studies may be due to the level of oxidative 
stress as well as the context. I have demonstrated that high levels of oxidative 
stress promote senescence in Mdm2S183A MEFs and tumor suppression in 
Mdm2S183A mice with carcinogen- and oncogene-induced tumors. Therefore, loss 
of Mdm2-S183 phosphorylation may also promote tumor suppression in mice 
with cancers driven by Wnt and Beta-catenin signaling, for example if there is an 
increase in the expression of FOXO transcription factors. In this case, tumor 
suppression in Wnt and Beta-catenin-driven tumors in Mdm2S183A mice may be 
mediated through senescence or other mechanisms including apoptosis.  
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Potential therapeutic implications 
 
ROS accumulation induced by the activation of PI3K/Akt pathway triggers 
Nrf2 nuclear localization (Menegon et al., 2016). Nrf2 is a transcription factor 
central to ROS detoxification and it activates the expression of antioxidant genes 
such as glutathione S-transferase and superoxide dismutase (Kansanen et al., 
2013). Inhibition of PI3K/Akt signaling in BRCA1-deficient tumors using BKM120 
or overexpression of PTEN sensitizes these tumors to elevated levels of ROS 
(Gorrini et al., 2014). Therefore, it is plausible that temporary inhibition of Mdm2-
S183 phosphorylation in cancer cells expressing hyperactive Akt  together with 
the administration of chemotherapeutic agents that perturb the redox balance 
such as Nrf2 inhibitor Brusatol, can further sensitize cells to oxidative stress.  
This can manifest as senescence and/or apoptosis thereby slowing down the 
development and/or progression of tumors with hyperactive PI3K/Akt signaling.  
 
In addition, sensitizing cells to ROS is critical especially in breast cancers 
that are resistant to PI3K/AKT signaling inhibitors. Withdrawal of PI3K/Akt 
inhibitors causes Akt-independent metabolic rewiring characterized by massive 
generation of ROS and profound proliferation defects, all of which are rescued by 
the administration of ROS scavengers such as NAC (Dermit et al., 2017). In this 
case, blocking Mdm2-S183 phosphorylation during the drug withdrawal period 
could sensitize these cells to senescence and halt the potential expansion of 
cancer cells resistant to PI3K/Akt inhibitors such as GDC-0941.  
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Most tumors disrupt p53 signaling and previous studies have shown that 
p53 reactivation can cause tumor regression in mice (Xue et al., 2007, Ventura et 
al., 2007). For instance, p53 reactivation in lung carcinomas triggers senescence 
and immune clearance of tumorigenic cells (Xue et al., 2007). Additionally, p53 
reactivation triggers apoptosis in lymphomas and senescence in sarcomas 
(Ventura et al., 2007). A significant percentage of tumors express functionally 
inert wild type p53 due to Mdm2 gene amplification like in the case of most 
human sarcomas (Oliner et al., 1992). Therefore, it is conceivable that 
progression of tumors may be halted by treatment of small molecule inhibitors 
that block Mdm2-S183 phosphorylation combined with agents that perturb redox 
homeostasis.  
  
Efforts to reactivate p53 by blocking Mdm2-S183 phosphorylation may 
have to be temporary. Inhibition of Mdm2-S183 phosphorylation in order to 
reactivate p53, especially in highly metabolic tumors, may also affect other 
normal tissues which are more prone to p53 induced-apoptosis such as the 
intestines and spleen. Additionally, Mdm2-mediated inhibition of p53 is required 
even in adult tissues. For instance, loss of Mdm2 function in mice expressing 
inducible p53 (p53ERTAM KI) causes the ablation of radiosensitive tissues and 
acute lethality in adult mice (Ringshausen et al., 2006).  Since blocking Mdm2-
S183 phosphorylation does not get rid of Mdm2, it is possible that this will not 
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affect normal tissues as is the case with other Mdm2 inhibitors such as MI-219 
which selectively triggers apoptosis in tumor cells (Shangary et al., 2008). MI-219 
still activates p53 in normal tissues, but at low levels that are not toxic and this is 
regulated through mechanisms that are yet to be elucidated. Furthermore, It is 
also important to consider the p53-independent effects of Mdm2 inhibition since 
Mdm2 binds to other effector proteins. My findings showing that Mdm2-S183 
phosphorylation prevents p53-mediated premature senescence triggered by 
oxidative stress will also be useful in potential therapeutic efforts for other 
disease states in which p53 and ROS play central roles including diabetes, 
cardiovascular disease, and aging.  
 
Activation of Akt allows cells to overcome the G2/M cell cycle checkpoint 
induced by DNA damage (Kandel et al., 2002). Akt is activated by ionizing 
radiation in some glioblastoma cell lines and inhibition of both EGFR and PI3K 
radisosensitizes these cells suggesting that Akt activation from radiation therapy 
promotes radioresistance (Li et al., 2009). Constitutive Akt activation is also 
observed in cisplatin resistant lung cancer, ovarian cancer, and glioma cell lines 
(Winograd-Katz and Levitzki, 2006). Activation of Akt in response to ionizing 
radiation reduces p53 levels in cell lines (Boehme et al., 2008). Therefore, it is 
also possible that Akt signaling following DNA damage promotes drug resistance 
in tumors by abrogating p53-mediated DNA damage responses such as cell 
cycle arrest and apoptosis. Since some therapeutic agents trigger ROS-mediated 
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apoptosis, combination therapies with compounds that inhibit Mdm2-S183 
phosphorylation in tumors with hyperactive Akt may promote cell death by 
exacerbating oxidative DNA damage. 
General conclusions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In this dissertation, I have shown that Mdm2-S183 phosphorylation by Akt 
at endogenous levels promotes normal cell proliferation under oxidative stress. 
Figure 4.1. Proposed Model. In the presence of oxidative stress from exposure 
to high oxygen, carcinogens, and oncogene expression, Mdm2-S183 
phosphorylation by Akt promotes Mdm2 nuclear localization and enhances p53 
degradation. As a result, this promotes cell proliferation by reducing p53-
mediated senescence  
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Mdm2-S183 phosphorylation enhances Mdm2 nuclear localization and stability 
resulting in diminished p53 levels and activity. Therefore, loss of this 
phosphorylation site increases p53 levels and activity thereby triggering 
premature senescence likely mediated by p53 in the presence of oxidative 
stress. 
 
The effects of Mdm2-S183 phosphorylation by Akt on p53-dependent 
responses are different from those exerted by  ATM- and c-Abl phosphorylation 
of Mdm2, but with some shared similarities in terms of  promoting tumor 
suppression. This reinforces the notion that Mdm2 post translational 
modifications are critical in influencing the type of p53-dependent responses to 
stress. This is important when thinking about therapeutic interventions such as 
p53 reactivation cancer. The type of stress contributing to different disease 
states, will require distinct ways of activating p53 through Mdm2 in order to 
obtain the desired therapeutic outcomes.  
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Introduction 
 
Role of p53 in glycolysis and mitochondrial respiration 
 
p53 has been shown to play pivotal roles in metabolic pathologies such as 
cancer and diabetes (Vousden and Ryan, 2009). Additionally, p53 generally 
favors an increase in oxidative phosphorylation whilst reducing glycolysis. Most 
cancer cells primarily depend on glycolysis for energy generation and p53 
transcriptionally activates genes that inhibit this pathway, suggesting that p53-
dependent regulation of glucose metabolism is consequential to tumor 
suppression. p53-dependent inhibition of glycolysis is mainly through the 
transcriptional regulation of metabolic genes. 
 
A plethora of metabolic genes are known to be activated by p53 as briefly 
discussed in chapter 1 and summarized in appendix figure 1. Briefly, p53 controls 
cellular glucose uptake by inhibiting the expression of glucose transporters Glut 
1,3 and 4 (Kruiswijk et al., 2015, Zhang et al., 2013) . Additionally, p53 also 
promotes mitochondrial respiration by activating the expression of key enzymes 
that control the flux of metabolites into the mitochondria such as PDK2 and GLS2 
(Hu et al., 2010, Suzuki et al., 2010, Contractor and Harris, 2012). p53 also 
inhibits glycolysis by shuttling glycolytic intermediates into the pentose phosphate  
pathway which is important for nucleotide synthesis  by triggering the expression 
of Tigar (Li et al., 2014). On the other hand, p53 activates the expression of 
genes that promote oxidative phosphorylation such as Sco2 and Parkin. SCO2 
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regulates the function of cytochrome oxidase complex and Sco2 deficient human 
cells that express wild type p53 display enhanced glycolysis that is similar to 
what is observed in p53-/- MEFs (Matoba et al., 2006). Furthermore, Parkin 
expression promotes oxidative phosphorylation by enhancing the expression of 
pyruvate dehydrogenase which is a crucial enzyme in pathways that generate 
acetyl-CoA which is a  major substrate for mitochondrial respiration Acetyl-coA 
(Zhang et al., 2011). 
 
Appendix figure 1: p53-dependent regulation of glucose metabolism. p53 
blocks cellular glucose uptake by is inhibiting glucose transporters Glut 1,3 and 
4. It inhibits glycolysis by triggering the expression of genes such as Tigar and 
Parkin, both of which play critical roles in promoting glycolysis.  On the other 
hand, p53 promotes oxidative phosphorylation by activating genes such as 
SCO2 and interacts with mtDNA Poly γ required to maintain the proper 
mitochondrial function. This image was directly adapted from (Liang et al., 2013) 
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Role of p53 in diabetes 
 
The two main forms of diabetes are characterized by either insulin deficiency due 
to impaired function or death of pancreatic beta islet cells (Type I) or diminished 
response to insulin due to inefficient insulin absorption by tissues such as 
muscles, liver and adipose tissue (Type II). Type II diabetes is often 
characterized by both insulin resistance and impaired beta-cell function 
(Cavaghan et al., 2000). Previous work has shown that p53 influences several 
aspects of diabetes. 
 
There is evidence to show that p53 is involved in the pathophysiology of 
diabetes, particularly in promoting insulin resistance. The idea that p53 activation 
affects insulin function came from a study showing that p53 negatively regulates 
expression of  the insulin receptor (Webster et al., 1996). In addition, p53 and 
p53-target genes are activated in the adipose tissues of obese and insulin 
intolerant mice (Yahagi et al., 2003). Various studies has been done using both 
in vitro and in vivo models to determine the role of p53 in molecular events 
governing the development of diabetes. For instance, p53 expression in adipose 
tissues of mice with type 2 diabetes-like disease under high fat diet promoted 
ROS generation, senescence and inflammation in the adipose tissue (Minamino 
et al., 2009). Loss of p53 ameliorated this phenotype and provided protection 
against insulin resistance. In addition, embryonic lethality in Lig4-/- mice caused 
by defective non-homologous end joining is rescued by the concomitant loss of 
 
  
103 
p53 (Tavana et al., 2010). However, Lig4-/-;p53-/- mice are susceptible to 
lymphomagenesis which is abrogated by the expression of apoptosis deficient 
p53 mutant (p53 R172P), but this results in acute diabetes and death. p53 R172P still 
retains the ability to trigger senescence  and cell cycle arrest, suggesting that 
p53-mediated senescence and apoptosis in the adipose tissue and pancreas 
promotes the development of diabetes. Furthermore, loss p53’s E3 ubiquitin 
ligase arf-bp1 in pancreatic beta cells led to diabetes and death in transgenic 
mice by 12 months and this phenotype was rescued by the loss of p53 (Kon et 
al., 2012). Taken together, these studies indicate that p53 activation in the 
adipose tissue and in the pancreas can trigger apoptosis or senescence. This 
potentially alters insulin production and sensing resulting in diabetes-like 
phenotypes including insulin resistance. 
 
Mdm2 inhibition using nutlin-3a activates p53-target genes known to 
enhance gluconeogenesis (Goldstein et al., 2013), suggesting that p53 promotes 
gluconeogenesis. Additionally, in a mouse model of diabetes and diet-induced 
obesity (Ay mice), p53 expression activates gluconeogenic genes in the liver 
(Minamino et al., 2009). Consistently, p53-/- mice exhibit reduced ability to trigger 
gluconeogenesis compared with wild type mice following starvation and this is 
mediated by p53-induced expression of pantothenate kinase-1 (Wang et al., 
2013). Insulin suppresses gluconeogenesis in healthy individuals but fails to do 
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so in some cases of type 2 diabetes. Therefore, promotion of gluconeogenesis 
by p53 may contribute to insulin resistance in humans and rodents. 
 
The effects of p53 in influencing insulin function is also observed in other 
insulin-responsive tissues like the skeletal muscles. p53 is expressed in skeletal 
muscles of aged rodents and is thought to triggers senescence often present in 
old muscle cells (Zwetsloot et al., 2013). Consistently, insulin signaling is 
impaired in muscle cells due to p53-dependent senescence triggered by 
ceramide (Jadhav et al., 2013). Additionally, in a rat model of Type II diabetes, 
exercise training lowered p53 and Tigar levels in skeletal muscles, consequently 
resulting in reduced levels of ROS and diminished insulin resistance (Qi et al., 
2011). p53 is also activated in endothelial cells of blood vessels in diabetic 
patients where it enhances endothelial senescence (Orimo et al., 2009). It has 
been established that dysfunctional insulin signaling in endothelial cells 
compromises insulin-mediated capillary recruitment thereby reducing blood flow 
and glucose uptake by skeletal muscles (Clark et al., 2003). Accordingly, in a 
mouse model of diet-induced obesity, p53 expression is elevated  in endothelial 
cells and this triggers insulin resistance which is ameliorated by endothelial cell-
specific p53 deficiency (Yokoyama et al., 2014). 
 
Given that p53 alters cellular glucose metabolism by favoring oxidative 
phosphorylation instead of  glycolysis, I posited that Mdm2-S183 phosphorylation 
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by Akt, which I have shown to lower p53 levels (Figure 2.7-2.8), promotes 
glycolysis in MEFs and  glucose intolerance in mice. In addition, phosphorylation 
of Mdm2-S183 enhanced p53-mediated senescence in the presence of oxidative 
stress. Therefore, since p53 expression can induce senescence and cell death in 
the pancreas and adipose tissues, I also hypothesized that blocking Mdm2-S183 
phosphorylation may promote insulin resistance whilst reducing glucose-
stimulated insulin release.  
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Results 
 
To evaluate whether Mdm2-S183 phosphorylation affects cellular glucose 
metabolism, I used the extracellular flux analyzer (Seahorse XFe 96) to perform 
glycolysis stress test (Appendix Figure 2) to measure glycolytic pathway capacity 
in Mdm2WT, Mdm2S183A, and p53-/- MEFs. Glycolysis produces lactate and H+, 
both of which are the major sources of media acidification during glycolysis 
stress test. First, the addition of glucose activates glycolysis leading to an 
increase in extracellular acidification rate (ECAR). Second, the addition of 
oligomycin, which inhibits ATP generation through mitochondrial respiration, 
causing a massive second increase in ECAR (glycolysis reserve). Lastly, the 
addition of 2-deoxyglucose (2-DG) totally abolishes glycolysis thereby bringing 
ECAR down to  levels similar to those present in starved cells at the  beginning of 
the experiment (glycolytic capacity). An increase in glycolysis is usually 
accompanied by a decrease in oxygen consumption rate (OCR) arising from the 
decrease in oxidative phosphorylation. 
 
 
 
 
 
 
 
 
Appendix Figure 2. Schematic diagram highlighting the different stages in a  
glycolysis stress test. Adapted from (Traba et al., 2016)  
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The glycolysis was significantly reduced in Mdm2S183A MEFs compared 
with Mdm2WT and p53-/- MEFs (Appendix Figure 3a-b). In addition, Mdm2S183A 
MEFs exhibited the lowest glycolytic capacity and glycolytic reserve, significantly 
different to the levels present in Mdm2WT and p53-/- MEFs. Accordingly, the 
reduction in glycolysis observed in Mdm2S183A MEFs also corresponded with 
elevated oxygen consumption rates which were significantly higher than in 
Mdm2WT and p53-/- MEFs, presumably from oxidative phosphorylation (Appendix 
Figure 3c). The oxygen consumption rate was lowest in p53-/- MEFs suggesting 
that loss of p53 reduces oxidative phosphorylation consistent with previous work 
in HCT116 cells (Matoba et al., 2006). This demonstrates that Mdm2 
phosphorylation, which leads to slightly elevated levels of p53 in low oxygen 
MEFs (Figure 2.5 b), reduces oxidative phosphorylation and promotes the 
metabolism of glucose via glycolysis.  
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Appendix Figure 3. Mdm2-S183 phosphorylation promotes glycolysis in 
MEFs. (A) Assessment of glycolysis, glycolytic capacity, and glycolytic reserve in 
low oxygen Mdm2
WT, Mdm2S183A, and p53-/- MEFs expressed as extracellular 
acidification rate (ECAR). (B) Quantification of glycolysis, glycolytic capacity, and 
glycolytic reserve in low oxygen Mdm2
WT, Mdm2S183A,  and p53-/- MEFs. (C) 
Assessment of oxygen consumption rates from glycolysis stress test performed 
in low oxygen Mdm2
WT, Mdm2S183A, and p53-/- MEFs. (n=3 MEF lines per 
genotype) 
A 
B 
C 
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Next, I explored the role of Mdm2-S183 phosphorylation in glucose 
homeostasis in vivo. To this end, I performed glucose tolerance tests in Mdm2WT 
and Mdm2S183A mice. I found that there was no significant differences in glucose 
tolerance between Mdm2WT and Mdm2S183A mice (Appendix Figure 4a). Glucose 
uptake from the blood is regulated by insulin. Therefore, I examined the effects of 
Mdm2-S183 phosphorylation on glucose-stimulated insulin release. I found that 
there was no significant difference in glucose-stimulated insulin release between 
Mdm2WT and Mdm2S183A mice (Appendix Figure 4b). These results indicate that 
Mdm2-S183 phosphorylation does not impact glucose tolerance and glucose-
stimulated insulin release in mice. Furthermore, I performed an insulin tolerance 
test and Mdm2S183A mice displayed significant insulin insensitivity compared with 
Mdm2WT mice (Appendix Figure 4c). This suggests that phosphorylation of  
Mdm2-S183 prevents insulin resistance in mice.  
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Appendix Figure 4. Mdm2 S183 phosphorylation promotes insulin 
resistance but not glucose tolerance and glucose-stimulated insulin 
release. (A) Glucose tolerance test performed in Mdm2
WT (n=8) and Mdm2S183A 
(n=7) mice fasted overnight and injected intraperitoneally with glucose (1g/kg). 
Data represents measurements of blood glucose concentration at the indicated 
time points. (B) Glucose-stimulated insulin release in Mdm2
WT (n=10) Mdm2S183A 
(n=9) mice fasted overnight and injected intraperitoneally with glucose (2 mg/g). 
Data represents insulin concentration expressed as a percentage of time zero. 
(C) Insulin tolerance test in Mdm2
WT (n=8) and Mdm2S183A (n=9) mice fed ad 
libitum and injected intraperitoneally with insulin (0.75 mU/g). Data represents 
measurements of blood glucose concentration at the indicated time points. 
Student’s T tests and ANOVA with Fisher’s tests *p<005 and **p<0.01.  
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Conclusions 
 
Preliminary studies examining the effects of Mdm2-S183 phosphorylation 
in glucose metabolism in vitro showed that Mdm2S183A  MEFs displayed reduced 
glycolysis and glycolytic capacity compared with Mdm2WT MEFs. It is possible 
that slightly elevated p53 protein levels in Mdm2S183A  MEFs triggered the 
expression of genes that promote oxidative phosphorylation and/or genes that 
block glycolysis. This may account for the diminished glycolysis observed in 
Mdm2S183A mice. Experiments exploring whether Mdm2-S183 phosphorylation 
affects glucose metabolism in vivo demonstrated that this phosphorylation event 
did not influence glucose tolerance as well as glucose-stimulated insulin release.  
It is possible that p53 levels were not different between Mdm2WT and Mdm2S183A 
mice since I would expect oxidative stress to be way lower in vivo than in low 
oxygen culture. In that case, the expression of p53-target genes supposed to 
promote the glucose uptake will be comparable  and therefore no difference will 
be observed in glucose tolerance and glucose-stimulated insulin release between 
Mdm2WT and Mdm2S183A mice.  Additionally, the phosphorylation of S163 may 
compensate for the loss of S183 and as a result, Mdm2S183A mice will behave 
more like Mdm2WT mice. These findings suggests that Mdm2-S183 
phosphorylation promotes glucose metabolism via glycolysis in vitro, but  does 
not influence glucose homeostasis in vivo. 
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Insulin tolerance tests revealed that Mdm2-S183 phosphorylation 
regulates insulin sensitivity in mice. Mdm2S183A mice exhibited significant insulin 
resistance compared with Mdm2WT mice. However, it is possible that Insulin 
resistance observed in Mdm2S183A mice may not due to defective beta islet cell 
function since Mdm2S183A mice are capable of releasing insulin at comparable 
levels with Mdm2WT mice. Therefore, insulin insensitivity in Mdm2S183A mice 
mostly likely stems from altered insulin sensitivity in other peripheral tissues. 
Since the mice used in this study harbor whole body Mdm2-S183A knock-in 
mutations, it is difficult to determine the mechanism governing the observed 
insulin intolerance in MdmS183A mice. For future studies, it will be more 
informative to generate mice with tissue specific Mdm2-S183A  or both Mdm2 
S163A and S183A mutations in tissues involved in insulin sensing.  
 
Loss of Mdm2-S183 phosphorylation may trigger p53 activation in some 
cancers that display high levels of ROS. Increased glycolysis observed in 
Mdm2S183A MEFs can be useful in in designing therapies for cancer. Small 
molecules capable of inhibiting Mdm2-S183 phosphorylation may trigger 
senescence and/or reduce glycolysis to the detriment of cancer cell survival. 
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 MATERIALS AND METHODS 
 
Animal studies 
Generation and genotyping of Mdm2S163A and Mdm2S183A mice. Mdm2 
mutant mice were generated by injecting a mixture of Cas9 mRNA (50ng/µl), 
sgRNA (25ng/µl), and single stranded oligonucleotides (100 ng/µl) into zygotes at 
the pronuclear stage. Resulting modified embryos were transferred into pseudo 
pregnant mice at 2.5 dpc and heterozygous mice obtained after three weeks and 
were later crossed to WT C57BL/6J mice acquired from The Jackson Laboratory 
for 9 generations. The intended missense mutations substituting serine to alanine 
on Mdm2 codon 163 and 183 introduced a BsrDI and ApaI restriction enzyme cut 
site, respectively. Therefore, to determine the presence of anticipated knock-in 
alleles, we performed genomic PCR to amplify regions harboring S163 and S183 
codons followed by BsrDI and ApaI restriction enzyme digestions, respectively. 
Digested PCR products were subjected to gel electrophoresis to confirm the 
genotypes. Additionally, we performed DNA sequencing of the regions harboring 
the 2 Mdm2 codons to further confirm the presence of the intended mutations 
and absence of off target mutations in the Mdm2 sequence.  
 
 
 
 
 
 
  
114 
Mdm2 -S163 gRNA 5' AGGAGATCCATTAGTGAGACAGG 3'  
Mdm2-S183 gRNA 5' GATCAAAGGACAGGGACCTGCGG 3'  
Mdm2 -S163 donor oligo 
5’_AAACCTTCATCTTCTGATTTAATTTCTAGACT
GTCTACCTCATCTAGAAGGAGATCCATTGCTGA
GACAGGTACATAGGGACATTATGTGACATACTA
AACAGTTGCTTGGTGTTTCCATTTT 3’ 
Mdm2-S183 donor oligo 
5’_TAATCTATAGAAGAGAACACAGATGAGCTAC
CTGGGGAGCGGCACCGGAAGCGCCGCAGGGC
CCTGTCCTTTGATCCGAGCCTGGGTCTGTGTGA
GCTGAGGGAGATGTGCAGCGGCGGCAGC 3’ 
Mdm2 S163A genotyping   
Forward Primer 5’ CCAGCATGCAAATGACTCTTG 3’ 
Reverse primer 5’ CTGGATTAAAGATGAGAGCCAC 3’ 
Mdm2 S183A genotyping   
Forward Primer 5' GAGCTTTATGTGTAGCTGAACAG 3’ 
Reverse primer 5' CAGTGCGCACAGAGCCCTG 3’ 
 
In vivo mice experiments. For the DNA damage experiments, mice were 
exposed to ionizing irradiation using a cesium-137 source (Gammacell 40) and 
were either monitored for survival or sacrificed at various time points to harvest 
tissues. To induce hepatocellular carcinoma, 2-week-old mice male were injected 
intraperitoneally with a single dose of 25mg/Kg diethylnitrosamine (DEN) (Sigma 
N0258) diluted in glyceryl trioctanoate (Sigma T9126). DEN treated mice were 
sacrificed after 40 weeks to determine tumor presence and burden. For the skin 
carcinogenesis experiments, 400nM of 7,12-dimethylbenz[a]-anthracene (DMBA) 
(sigma D3254) dissolved in acetone was topically applied to 8 week old mice. 
Two weeks after DMBA initiation, tumor formation was promoted by topical 
application of 10nM 12-O-tetradecanoylphorbol-13-acetate (TPA) (Sigma P8139) 
dissolved in acetone, twice weekly for up to 35 weeks. To study Ras-induced 
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lung tumorigenesis, 8-week-old mice were intranasally intubated with 125μL of 
2.5×107 PFU of purified Adeno-Cre virus (University of Iowa, Gene Transfer 
Vector Core) and sacrificed after 7.5 months to harvest lung tissues for 
immunohistochemical analyses. Glucose tolerance, insulin tolerance, and 
pyruvate challenge tests. To determine insulin and glucose tolerance, mice were 
fed a standard chow diet for 8 wks. Glucose tolerance tests were performed by 
intraperitoneal injection of 1g/kg glucose (VWR 4908-06) and measurement of 
blood glucose concentration at various time points.  To measure glucose-
stimulated insulin section, mice were fasted overnight and were injected 
intraperitoneally with glucose (2 g/Kg) followed by blood insulin concentration 
measurements at various time points. Insulin in plasma was measured by 
multiplexed ELISA using a Luminex 200 machine (Millipore). To determine insulin 
resistance, mice fed ad libitum were injected intraperitoneally with insulin (0.75 
mU/g) followed by measuring blood glucose concentration at various time points. 
All animal procedures complied with guidelines set by Institutional Animal Care 
and Use Committee at the University of Massachusetts Medical School.      
 
Cell Culture and In vitro treatments  
MEFs were generated from E13.5 embryos and cultured in DMEM 
supplemented with 1% penicillin-streptomycin (Thermo 15140122), 1% -
mercaptoethanol (sigma M3148), and 15% fetal bovine serum (Hyclone SH 
30071.03). Low oxygen MEFs were cultured in a hypoxic incubator (5% oxygen) 
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in media further supplemented with 5mM N-acetyl cysteine (Sigma A9165) and 
deoxygenated by bubbling with trigas (5% CO2, 5% O2, Balance N2) (Airgas).  
 
To stain for senescence associated β-galactosidase, MEFs were fixed 
with 4% paraformaldehyde and incubated overnight with staining solution (5mM 
potassium ferricyanide; 5 mM potassium ferrocyanide; mM MgCl2; 150mM NaCl; 
1mg/ml X-gal) dissolved in 40mM citrate/sodium phosphate buffer at pH 6. To 
assay for colony formation, 2x104 low and high oxygen MEFs were cultured for 
10 days, fixed with cold methanol for 10 minutes and stained with 0.05% crystal 
violet dissolved in 1% methanol.  
 
To determine the levels of ROS, high and low oxygen MEFs were 
subjected to DCFDA staining assay following manufacture’s protocol (Abcam 
113851). Briefly, 1.5 x 105 passage 3 high and low oxygen MEFs were stained 
with 25uM DCFDA for 1 hour at 37OC. DCF fluorescence intensity was measured 
using flow cytometry Ex/Em = 485/535 nm.  
 
To determine the percentage of cells in S phase following DNA damage, 
passage 2 MEFs cultured at low oxygen with NAC were exposed to 4 Gy ionizing 
radiation (Gammacell 40), 250nM doxorubicin hydrochloride (Sigma D1515), and 
5µm Etoposide (Sigma E1383) overnight, and pulse labeled with 50µM BrdU 
(Sigma B5002) for 3hrs. Treated MEFs were then fixed in 70% ethanol and 
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incubated with anti-BrdU antibody (BD 347583) and Propidium Iodide (Sigma 
P4170) followed by flow cytometry analyses. Resulting data was analyzed using 
FlowJo software.  
 
To assay for lipid peroxidation, we used lipid peroxidation microplate 
assay (Sigma MAK085) according to manufacturer’s instructions. Briefly, 
passage 3 high and low oxygen MEFs were collected, lysed, and the amount of 
lipid peroxidation was determined by calorimetric  measurement of MDA at 
532nm from reacting 50ug whole cell lysate with thiobarbituric acid. The amount 
of MDA was normalized to the amount of protein.  
 
For measuring apoptosis, we used the Dead Cell Apoptosis Kit with 
Annexin V FITC and PI, for flow cytometry (Thermo V13242) and analyzed the 
data to quantify both early and late apoptotic cells using Flowjo software. Flow 
cytometry was performed by the Flow Cytometry Core at UMASS Medical 
School.  
 
Immunoblotting   
Whole cell and tissue protein lysates were made using NP-40 lysis buffer 
(50 mM; Tris-HCl; pH 7.5; 150 mM NaCl; 0.5% NP-40; 20% Glycerol) 
supplemented with protease inhibitor cocktail (Roche 11873580001) and 
phosphatase inhibitor cocktail (Roche 4906845001). Lysates (50µg) were 
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subjected to SDS-PAGE and transferred to PVDF membranes. Proteins were 
detected using antibodies against vinculin (Sigma V9131), p53 (Leica NCL-L-
p53-CM5p), phospho-p53 (S15) (CST 9284), p21 (Novus NBP2-29463), Mdm2 
(Novus NBP1-02158), phospho-Akt (S473) (CST 9271), phospho-Akt (T308) 
(CST 9275), Akt (pan) (CST 2920) and p16 (Santa Cruz sc-377412) in 5% non-
fat milk. Membranes were developed using Clarity Western ECL Substrate 
(BioRad 1705060) and imaged using Chemidoc Molecular Imaging System 
(BioRad). Quantification of western blot band intensity was done using Image J 
software.  
 
Immunofluorescence 
Passage 3 high and low oxygen MEFs were fixed in 4% 
paraformaldehyde, permeabilized with 0.2% Triton-X100 in PBS for 15 min, 
treated with 200ug/ml RNase A (Sigma R4875) at 37 °C for 1 hour, and blocked 
in 1% bovine serum albumin with 0.2% Triton-X100 in PBS for 30 minutes. Fixed 
MEFs were subsequently incubated overnight at 4 °C in primary 8-Oxo-2'-
deoxyguanosine (ab206461) antibody followed by secondary Alexa Fluor488-
conjugated goat anti-mouse antibody (Abcam 150113) for 1 hour. Cells were 
mounted with ProLong™ Diamond Antifade Mountant with DAPI (Thermo 
P36962) to stain for nuclear DNA.   
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To determine ROS production following DEN injection in two-week-old 
mice, dihydroethidium (DHE) (Thermo D1168) was used to measure ROS 
production in 5um frozen cryosections incubated with 0.1 mM DHE dissolved in 
HEPES-Tyrode buffer solution (132 mM NaCl, 4 mM KCl, 1 mM CaCl2, 0.5 mM 
MgCl2, 9.5 mM HEPES, and 5 mM glucose) for 15 min at room temperature. 
Images were captured using Zeiss Axioplan 2 microscope (Zeiss, Thornwood, 
NY, USA). 
 
Gene Expression 
To quantify gene expression levels using qPCR, RNA was isolated from 
high and low oxygen Passage 3 MEFs or mouse tissues using RNeasy Plus Mini 
Kit (Qiagen 74134) and cDNAs were generated using SuperScript™ III Reverse 
Transcriptase (Invitrogen 18080093). qPCR was done using Power SYBR™ 
Green PCR Master Mix (Applied Biosystems 4367659) with StepOnePlus Real-
Time PCR System (Applied Biosciences). The comparative CT method (2−∆∆CT) 
was used to determine fold differences between the target gene and the 
reference gene Rplp0. Sequences for primers were as follows; 
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p21 Forward 5’ CTGAGCGGCCTGAAGATT 3’ 
p21 Reverse 5’ ATCTGCGCTTGGAGTGATAG 3’ 
    
Mdm2 Forward 5’ AGTCTCTGGACTCGGAAGATTA 3’  
Mdm2 Reverse 5’ CTGTATCGCTTTCTCCTGTCTG 3’ 
    
Rplp0 Forward 5’ CTGAGTACACCTTCCCACTTAC3’  
Rplp0 Reverse 5’ CTCTTCCTTTGCTTCAGCTTTG 3’ 
    
Sestrin-1 Forward 5’ ACTGCGTCTTTGGCATCA 3′  
Sestrin -1 Reverse  5’ CATCCTACGGGTCGTCTTCT 3′ 
    
Sestrin-2 Forward 5’ TTCAGGGAGAAGCGTTTGC 3′  
Sestrin -2 Reverse  5’ ACACACTCTATCACTGGCACC 3′ 
    
Pai-1 Forward 5’ TGCATCGCCTGCCATTG 3’  
Pai-1 Reverse 
5 ’GGACCTTGAGATAGGACAGTGCTT 
3’ 
    
Pai-2 Forward 5′ CACCACAGGGGGATTATTTG 3’  
Pai-2 Reverse 5 ′GGATGCGTCCTCAATCTCAT 3’ 
 
Histology 
Mouse tissues were fixed in 10% buffered formalin for overnight and 
embedded in paraffin, sectioned and stained with Hematoxylin and Eosin (HE). 
To assay for cell death in vivo, fixed tissues were stained with TUNEL using In 
situ Cell Death Detection Kit (Roche 11684817910) according to manufacturer’s 
protocol. Paraffin embedded livers from DEN treated mice were incubated with 
glutamine synthetase antibody (Abcam 73593) to stain liver tumors, -H2A.X 
(phosphor S139) (Abcam 11174) to detect DNA damage, and the 
aforementioned TUNEL kit to assay for cell death.  
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To stain skin tissue from DMBA/TPA treated mice for senescence 
associated -galactosidase, skin sections were briefly fixed 4% 
paraformaldehyde for 5 minutes and incubated for 4 hours at 37 0C in the dark in 
a staining solution (5mM potassium ferricyanide; 5mM potassium ferrocyanide; 
2mM MgCl2; 150mM NaCl; 1mg/ml X-gal) dissolved in 40mM citrate/sodium 
phosphate buffer at pH 6.  The tissues were subsequently washed in PBS and 
fixed overnight in 10% buffered formalin and embedded in paraffin. Sections 
were counterstained with Nuclear Fast Red and images were taken using a light 
microscope (Zeiss) outfitted with Axiocam camera. 
  
Lungs from mice that inhaled purified Adeno-Cre virus to activate mutant 
K-ras expression were sacrificed after 7.5 months and lungs perfused for 5 
minutes and fixed overnight with 10% formalin. Lungs were embedded in paraffin 
and sections were stained with HE. The area occupied by tumors were 
calculated using ImageJ software. 
 
Statistical analysis 
Statistical analyses were performed using either Microsoft Excel or 
GraphPad Prism Software to perform Student ‘s T tests and ANOVA with the 
Fisher’s tests. Log Rank tests were used to determine p values for all survival 
curves and 2 tests were used to determine the p values for Mendelian ratios.  
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